EXPLORING THE ALIGNMENT OF ICH REGIONS IN RELATION TO THE ACCELERATED APPROVAL OF FIRST-IN-CLASS DRUGS

Research dissertation presented in partial fulfilment of the requirements for the degree of MSc in Pharmaceutical Business and Technology

Innopharma Faculty of Pharmaceutical Sciences

Griffith College Dublin

Dissertation Supervisor: Philip Byrne

Conor Kennedy

August 2024

Candidate Declaration

Candidate Name: Conor Kennedy

I hereby confirm that the dissertation entitled:

Exploring the alignment of ICH regions in relation to the accelerated approval of first-in-class drugs, submitted in partial fulfilment of the requirements for the degree of MSc in Pharmaceutical Business & Technology is the result of my own work and that where reference is made to work of others, due acknowledgement is given.

Candidate Signature: Conor Kennedy

Date: 10 SEP 2024

Supervisor Name: Philip Byrne

Supervisor Signature:

Date:

Acknowledgements

I would like to thank my supervisor Philip Byrne for sharing his knowledge and experience in guiding me through this dissertation. I would also like to share my appreciation to my family and friends for motivating me throughout this process, particularly when I wanted to give up on this study. Thank you for believing in me.

Table of contents

List of Figures

List of Tables

List of Abbreviations

ICH - International Council for Harmonization

EU - European Union

USA - United States of America

EMA - European Medicines Agency

FDA - Food and Drug Administration

PMDA - Pharmaceuticals and Medical Devices Agency

PRIME - PRIority MEdicines

RWE - Real-World Evidence

ATMP - Advanced Therapy Medicinal Products

CMA - Conditional Marketing Authorization

IRB - Institutional Review Board

RWD - Real-world data

IMI - Innovative Medicines Initiative

HTA - Health Technology Assessment

MDR - Medical Device Regulation

IVDR - In Vitro Diagnostic Regulation

WHO - World Health Organization

CRO - Contract Research Organization

SPSS - Statistical Product and Service Solutions

GDPR - General Data Protection Regulation

QA - Quality Assurance

AI - Artificial Intelligence

Abstract

This study examines the regulatory challenges and organizational strategies in the pharmaceutical industry, focusing on the accelerated approval of first-in-class drugs in International Council for Harmonization (ICH) regions (European Union (EU), United States of America (USA), Japan). The objective is to identify the primary obstacles faced by pharmaceutical organizations in obtaining regulatory approval and to explore effective strategies to navigate these challenges. A quantitative research methodology was employed, utilizing structured surveys distributed to regulatory professionals with direct experience in regulatory submissions for first-in-class drugs.

The results indicate that the major challenges include stringent regulatory requirements, complex clinical trial designs, data quality and integrity issues, communication barriers with regulatory agencies, and tight timelines. Significant variability in regulatory requirements was observed across ICH regions, particularly in documentation, approval timelines, and data quality expectations.

Effective organizational strategies identified include early engagement with regulatory agencies, leveraging accelerated approval pathways, investing in advanced clinical trial designs, collaborating with external experts, and implementing robust quality management systems. The study finds that while these strategies are generally perceived as effective, their success can vary based on regional regulatory environments and organizational contexts.

The study concludes that harmonizing regulatory guidelines across ICH regions, enhancing transparency and communication between regulatory agencies and pharmaceutical companies, expediting review times, and allowing more flexibility in clinical trial requirements are critical for improving the efficiency of the regulatory approval process. These findings offer practical insights for pharmaceutical organizations and policymakers, emphasizing the need for coordinated efforts to streamline regulatory practices and enhance patient access to innovative therapies.

Chapter One: Introduction

1.1. Overview

The rapid advancement of medical science has led to the development of innovative medications known as first-in-class drugs. These drugs represent groundbreaking therapeutic approaches, often targeting novel pathways or mechanisms of action, and offer promising treatment options for patients with serious or life-threatening conditions. Unlike follow-on drugs, which are based on established mechanisms, first-in-class drugs introduce entirely new methods for treating diseases, offering hope for conditions that previously had limited or no treatment options.
The approval process for first-in-class drugs, however, is inherently complex and time-consuming. Regulatory authorities, such as the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, require thorough evaluation of quality, safety and efficacy. This rigorous assessment process involves multiple stages, including preclinical studies, clinical trials (Phase I, II, and III), and extensive documentation. These requirements ensure that the drugs are both safe and effective for public use but also contribute to significant delays in bringing these innovative treatments to market ((Bode, 2020); (Teixeira *et al.*, 2020)).

In recent years, there has been a growing interest in accelerating the approval of these innovative medications to expedite their availability to patients who urgently need them. Accelerated approval pathways, such as the FDA's Breakthrough Therapy designation and the EMA's PRIority MEdicines (PRIME) scheme, have been introduced to facilitate quicker access to promising therapies. These pathways allow for earlier and more frequent interactions between the developers and regulatory bodies, aiming to resolve potential issues proactively and expedite the review process (Kumari *et al.*, 2024).
The ICH plays a key role in facilitating global regulatory convergence and harmonization. Established in 1990, the ICH brings together regulatory authorities and pharmaceutical industry representatives from Europe, the US, Japan, and other regions to develop and implement unified standards. These standards aim to streamline drug development and approval processes, reduce duplication of testing, and ensure consistent quality and safety of medicines globally. Despite these efforts, the extent to which ICH regions align in their approach to the accelerated approval of first-in-class drugs remains an area of ongoing exploration ((Horgan *et al.*, 2020); (Asano *et al.*, 2021)).

1.2. Aims and Objectives of the Dissertation

The primary aim of this research is to explore the alignment of ICH regions in the accelerated approval of first-in-class drugs and to identify strategies to improve this process. This aim will be achieved through the following specific objectives:

Review the Global Regulatory Landscape: Conduct a comprehensive review of regulatory frameworks governing first-in-class drug approval processes in ICH regions, focusing on the founding regions; the EU, US, and Japan. This will include an analysis of regulatory guidelines, approval pathways, and the roles of key regulatory agencies.

- *Detailed Analysis:* Investigate the specific regulatory guidelines and pathways that each region employs. Understand the roles and interrelationships between different regulatory bodies and how they influence the approval process.

- *Comparative Study:* Compare and contrast the regulatory frameworks to highlight similarities and differences, providing a clearer picture of the global regulatory landscape.

Identify Specific Approval Challenges: Identify and analyze the specific challenges encountered by pharmaceutical organizations during the approval processes for first-in-class drugs. This objective will explore regulatory, clinical, and evidentiary hurdles that can delay or complicate the approval process. Examples of these challenges include meeting diverse regulatory requirements, conducting region-specific clinical trials, and managing different expectations regarding safety and efficacy data.

- *Regulatory Hurdles:* Investigate the complexities involved in navigating different regulatory requirements and guidelines.
- *Clinical Trial Challenges:* Examine the difficulties in designing and conducting clinical trials that meet the stringent requirements of regulatory agencies.
- *Data Integrity and Quality:* Explore issues related to maintaining data integrity and meeting the high standards of evidence required for approval.

Examine Organizational Strategies: Investigate initiatives and strategies implemented by both pharmaceutical and regulatory organizations to address the challenges in obtaining and granting regulatory approval for novel therapies. This includes examining case studies of successful and unsuccessful approval processes, the role of regulatory intelligence, and strategies such as early engagement with regulatory agencies and adaptive clinical trial designs.

- *Case Studies:* Provide detailed case studies that illustrate successful strategies and highlight lessons learned from unsuccessful attempts.
- *Regulatory Intelligence:* Analyze the role of regulatory intelligence in anticipating and addressing potential regulatory issues.

Propose Evidence-based Recommendations: Propose evidence-based strategies and recommendations to enhance the efficiency and effectiveness of regulatory approval processes for first-in-class drugs. The aim is to facilitate timely access to innovative treatments for patients while ensuring that regulatory standards and patient safety are maintained. Recommendations will be developed based on the findings from the previous objectives and will consider both short-term improvements and long-term strategic changes.

- *Short-term Improvements:* Identify immediate actions that can be taken to streamline the approval process.
- *Long-term Strategies:* Develop strategic recommendations that require broader changes in regulatory practices and policies.

1.3. Research Questions

This research seeks to answer the following questions:

<u>What are the primary regulatory challenges in the approval of first-in-class drugs?</u>

- How do different regions define and implement regulatory requirements for first-in-class drugs?
- What are the most common hurdles faced by pharmaceutical companies during the approval process?

How do different pharmaceutical companies navigate these challenges?

- What strategies are used by companies to meet regulatory requirements and expedite the approval process?
- How do these strategies vary across different regions and types of organizations?

What strategies are perceived as most effective in overcoming regulatory hurdles?

- Which strategies have been successful in previous approval processes?
- What role does early engagement with regulatory agencies play in the approval process?

How can the regulatory approval process be improved to facilitate faster access to innovative therapies?

- What specific changes in regulatory practices could enhance the efficiency of the approval process?
- How can regulatory agencies and pharmaceutical companies collaborate more effectively to achieve this goal?

1.4. Significance of the Research

The significance of this research lies in its potential to streamline the regulatory approval process for first-in-class drugs, thereby reducing the time and cost associated with bringing innovative therapies to market. By identifying effective strategies and recommending improvements, this study aims to benefit both pharmaceutical companies and regulatory agencies, ultimately enhancing patient access to new treatments. Key points of significance include:

- Practical Implications: Provide actionable insights that pharmaceutical companies can use to navigate regulatory challenges more effectively.
- Policy Recommendations: Offer evidence-based recommendations that regulatory agencies can implement to improve the efficiency and effectiveness of the approval process.
- Global Health Impact: Contribute to the broader goal of improving global health by facilitating quicker access to innovative therapies for patients.

1.5. Access and Research Ethics Issues

Access to data was obtained through surveys distributed to regulatory professionals in the pharmaceutical industry. Confidentiality and anonymity were maintained throughout the research process.

1.6. Structure of the Research

This dissertation is structured as follows:

Chapter 1: Introduction: Provides the background information, identifies the research gap, outlines the hypothesis, states the research aims and objectives, and gives an overview of the thesis structure.

Chapter 2: Literature Review: Reviews existing literature on regulatory approval processes, challenges, and strategies in ICH regions. It provides a critical analysis of the current state of knowledge and identifies gaps that the current research aims to fill. The

literature review will cover key topics such as regulatory frameworks, accelerated approval pathways, and the impact of regulatory harmonization efforts.

Chapter 3: Research Methodology: Describes the research design and approach for obtaining primary data. It outlines the philosophical approach, research methods (such as surveys), and data collection strategies. The methodology section also discusses the selection criteria for participants, the conceptual framework guiding the research, and potential ethical issues and how they will be addressed.

Chapter 4: Findings and Analysis: Presents and analyzes the primary research data. It uses descriptive and inferential statistical methods to interpret quantitative data and thematic analysis for qualitative data. The findings are compared and contrasted with those from the literature review to draw comprehensive conclusions about the regulatory challenges and strategies in ICH regions.

Chapter 5: Conclusions and Recommendations: Summarizes the research findings and their implications. It provides practical and academic recommendations for improving regulatory approval processes. The chapter also discusses the limitations of the study and suggests areas for future research. Additionally, it includes a reflective section where the researcher can discuss personal insights and learning experiences gained during the dissertation process.

Chapter Two: Literature Review

2.1 Regulatory Landscape and Alignment

2.1.1 Introduction

The regulatory landscape for drug approval processes is characterized by its dynamic and complex nature, reflecting ongoing efforts to harmonize standards and streamline procedures across ICH regions. The primary goal of regulatory harmonization is to facilitate global access to safe and effective medicines. However, achieving alignment among diverse regulatory authorities poses significant challenges due to differences in regulatory frameworks, cultural nuances, and healthcare priorities. This section provides a detailed overview of the regulatory landscape and alignment efforts within ICH regions, including the EU, USA, and Japan.

2.1.2 Regulatory Frameworks and Harmonization Efforts

The ICH plays a crucial role in facilitating global regulatory convergence and harmonization. It aims to streamline drug development and approval processes across different regions, promoting consistency and transparency in regulatory decision-making (ICH, 2024). The ICH guidelines serve as the foundation for harmonized regulatory practices, addressing various aspects of pharmaceutical development, including quality, safety, and efficacy standards.

Harmonization Aspect	EMA	FDA	PMDA
Guideline Development	ICH guidelines, EMA guidelines	ICH guidelines, FDA guidelines	ICH guidelines, PMDA guidelines
Approval Process	Centralized Procedure	Risk-based Approach	Quality, Safety, Efficacy Focus
Expedited Programs	Accelerated Assessment	Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review	Sakigake Designation, Conditional Early Approval
Real-World Evidence (RWE) Integration	Emphasized, EMA guidelines	Emphasized, FDA guidelines	Increasing focus, PMDA guidelines
Advanced Therapy Regulation	Specific guidelines for Advanced Therapy Medicinal Products (ATMP)	Focus on gene and cell-based treatments	Collaborative review for advanced therapies

Bilateral Agreements	Collaborates with FDA, PMDA	Collaborates with EMA, PMDA	Collaborates with EMA, FDA

Table 1: Harmonization efforts **(Teixeira *et al.*, 2020; Asano *et al.*, 2021; ICH, 2024)**

In the EU, the EMA is responsible for the scientific evaluation, supervision, and safety monitoring of medicines. The EMA operates under a centralized procedure for drug approval, which allows pharmaceutical companies to submit a single marketing authorization application to the EMA for approval in all EU member states. This centralized approach aims to reduce duplication of efforts and ensure consistent regulatory standards across the EU (Teixeira et al., 2020).

In contrast, the FDA employs a risk-based approach to drug approval, prioritizing the assessment of safety and efficacy endpoints in clinical trials. The FDA's regulatory framework includes various expedited programs, such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review, designed to facilitate the development and approval of drugs that address unmet medical needs (Kumari et al., 2024)

Japan's PMDA focuses on ensuring the quality, safety, and efficacy of pharmaceuticals and medical devices. The PMDA collaborates with the EMA and FDA through bilateral agreements and participation in ICH activities to harmonize regulatory standards and promote global drug development (Asano et al., 2021).

2.1.3 Challenges in Regulatory Alignment

Achieving regulatory alignment among ICH regions is challenging due to differences in regulatory frameworks, scientific evaluation criteria, and policy objectives. One critical aspect of regulatory alignment is the interpretation and application of scientific evidence in decision-making. Regulatory authorities employ diverse approaches to evaluate clinical data, weighing the balance of benefits and risks associated with new therapies (Gonçalves, 2022).



***Figure 1: Average drug approval timelines by region* (CIRS, 2022)**

For instance, the EMA emphasizes the concept of "added therapeutic value," focusing on the incremental benefit of new drugs over existing treatments. This approach aims to ensure that new therapies provide meaningful improvements in patient outcomes (Teixeira et al., 2020). In contrast, the FDA's risk-based approach prioritizes the assessment of safety and efficacy endpoints, often accepting surrogate endpoints or adaptive trial designs in certain cases (Kumari et al., 2024).

The emergence of advanced therapies, such as gene and cell-based treatments, presents additional challenges for regulatory alignment. These innovative therapies require novel regulatory approaches to accommodate their unique characteristics and ensure patient safety. Regulatory agencies must adapt their review processes and evaluation criteria to assess the safety, efficacy, and quality of these advanced therapies, fostering an environment conducive to their development and commercialization ((Horgan et al., 2020); (Bouwman et al., 2020).

2.1.4 Expedited Programs

The EMA, FDA, and PMDA have developed several expedited programs to facilitate the faster approval of drugs that address unmet medical needs or provide significant therapeutic advancements. These programs are designed to accelerate the development and review process, ensuring that critical treatments reach patients more quickly.

2.1.5 EMA Expedited Programs

The EMA offers several expedited programs to streamline the approval of important therapies:

Accelerated Assessment: This program aims to shorten the EMA's review time for medicines of major public health interest, particularly those that address unmet medical needs. The review process is reduced from 210 days to 150 days, enabling faster access to essential treatments (Teixeira et al., 2020).

Conditional Marketing Authorization (CMA): This pathway allows for the early approval of a medicine with less comprehensive data than normally required, provided that the benefit of immediate availability outweighs the risk of less comprehensive data. It is applicable to medicines that address unmet medical needs, such as orphan drugs or treatments for serious diseases (Ofori-Asenso et al., 2020).

PRIME: This scheme offers early and proactive support to developers of promising medicines that target unmet medical needs. It provides enhanced interaction and dialogue with the EMA, ensuring efficient development plans and accelerated assessment of marketing authorization applications (Cavaleri et al., 2021).

2.1.6 FDA Expedited Programs

The FDA has established multiple expedited programs to facilitate the rapid development and approval of therapies:

Fast Track: This designation is granted to drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent interactions with the FDA and the possibility of rolling review, where the company can submit completed sections of the application for review rather than waiting until the entire application is complete (Kumari et al., 2024).

Breakthrough Therapy: This designation is given to drugs that show substantial improvement over existing therapies in preliminary clinical evidence. It provides intensive guidance from the FDA and a commitment to expedite the development and review processes (Eichler et al., 2019).

Accelerated Approval: This pathway allows drugs for serious conditions that fill an unmet medical need to be approved based on a surrogate endpoint. This can significantly shorten the time required for the drug to be available to patients, with post-marketing studies required to confirm the anticipated clinical benefit (Wang et al., 2022) .

Priority Review: This designation means the FDA will review the application within six months instead of the standard ten months. It is granted to drugs that offer significant improvements in treatment, diagnosis, or prevention of serious conditions (Kolochavina, 2021).



Figure 2: Proportion of Drugs Approved through Expedited Programs by the FDA **(CDER, 2024)**

2.1.7 PMDA Expedited Programs

The PMDA in Japan also offers expedited pathways to enhance the availability of critical treatments:

Sakigake Designation: This program is aimed at promoting the early introduction of innovative pharmaceutical products. It offers priority consultation, substantial pre-application review, and a shortened review period, thereby accelerating the approval process for groundbreaking therapies (Asano et al., 2021).

Conditional Early Approval: Similar to the EMA's CMA, this pathway allows for the approval of drugs based on less comprehensive data if the drug addresses an unmet medical need and if its benefit-risk balance is favorable. Post-marketing studies are typically required to confirm the drug's efficacy and safety (Horgan et al., 2020).

Priority Review: The PMDA provides priority review status to drugs that offer significant therapeutic benefits over existing treatments. This expedited review process aims to make important new therapies available to patients more quickly (Teixeira et al., 2020).

These expedited programs reflect the regulatory agencies' commitment to balancing the need for thorough evaluation of new drugs with the urgency of making potentially life-saving treatments available to patients as soon as possible. By leveraging these pathways, pharmaceutical companies can navigate the regulatory landscape more efficiently, ultimately enhancing patient access to innovative therapies.

2.1.8 Policy Objectives and Public Health Priorities

Regulatory alignment also encompasses broader policy objectives, including access to medicines and public health priorities. Disparities in healthcare infrastructure, economic development, and disease burden influence regulatory decision-making and market access dynamics in ICH regions (Jackson et al., 2024). For instance, the concept of

"tiered" or "staggered" regulatory review pathways recognizes the varying healthcare needs and resource constraints across regions, allowing for tailored approaches to drug approval and access (Eichler et al., 2019).

Furthermore, regulatory agencies are increasingly focused on incorporating real-world evidence (RWE) into the drug approval process to enhance decision-making and address the limitations of traditional clinical trials. RWE provides valuable insights into the safety and effectiveness of therapies in real-world settings, complementing data from randomized controlled trials (Cave et al., 2019).

Advanced Therapy Regulation Aspect	EMA	FDA	PMDA
Guidelines for ATMPs	Established	Established	Collaborative Review
Focus Areas	Gene and cell-based treatments	Gene and cell-based treatments	Advanced Therapies
Collaborative Efforts	Works with FDA, PMDA	Works with EMA, PMDA	Works with EMA, FDA

Table 2: Advanced Therapy Regulation **(Iglesias-Lopez *et al.*, 2019; EMA, 2024a; PMDA, 2024)**

Post-COVID-19 Regulatory Landscape

The COVID-19 pandemic has further highlighted the need for regulatory agility and collaboration among global regulatory authorities. The rapid development and approval of COVID-19 vaccines demonstrated the potential for expedited regulatory pathways and real-time data sharing to accelerate the availability of critical therapies (Cavaleri et al., 2021). This experience has prompted regulatory agencies to explore new approaches and frameworks to enhance preparedness for future public health emergencies and ensure timely access to innovative treatments (Horgan et al., 2020).

2.2 Challenges in the Drug Approval Process

2.2.1 Introduction

The drug approval process is fraught with complexities and uncertainties that can impede timely access to innovative therapies. Regulatory requirements, scientific uncertainties, and market dynamics contribute to the myriad challenges faced by pharmaceutical companies seeking to bring new drugs to market. Understanding and addressing these challenges is crucial for optimizing drug development strategies and enhancing patient access to life-saving treatments.

2.2.2 Regulatory Requirements and Variability

One of the primary challenges in drug approval processes is the variability in regulatory requirements across different jurisdictions. Regulatory authorities, such as the FDA, EMA, and PMDA, have distinct guidelines and standards for evaluating clinical data, which can lead to different outcomes in the approval process. For instance, while the FDA may accept surrogate endpoints or adaptive trial designs in certain cases, the EMA may require more stringent evidence of clinical efficacy and safety before granting approval ((Omae et al., 2022);(Vallano et al., 2023)).

Moreover, the interpretation and acceptance of clinical trial data by regulatory authorities can vary significantly, posing challenges for pharmaceutical companies in designing studies that meet diverse regulatory expectations. Differences in trial design preferences, statistical methodologies, and data requirements necessitate careful planning and coordination to ensure alignment with regulatory standards and optimize the likelihood of successful approval (Botros et al., 2022).



Figure 3: Complexity of Regulatory Requirements (Teixeira et al., 2020; Franco et al., 2023)

A comparative analysis of drug approval processes in the US and Canada highlights these challenges. In the US, the FDA's flexibility in accepting surrogate endpoints contrasts with Canada's Health Canada, which often requires more extensive clinical evidence, reflecting a more conservative approach (Botros et al., 2022). This discrepancy underscores the need for pharmaceutical companies to tailor their clinical trial designs to meet the specific requirements of each regulatory body.

Regulatory Authority	Evidence Required	Surrogate Endpoints
FDA	Surrogate Endpoints, Adaptive Trials	Yes
EMA	Comprehensive Clinical Data	Yes
PMDA	Quality, Safety, Efficacy focus	Yes

***Table 3: Comparison of Evidence Requirements and Acceptance of Surrogate Endpoints by Regulatory Authority* (Schuster Bruce *et al.*, 2019; CDER, 2021; Maeda *et al.*, 2023)**

2.2.3 Scientific Uncertainties and Clinical Data

Scientific uncertainties inherent in the drug development process further complicate the regulatory landscape. Early-phase clinical trials often involve small sample sizes, limited data availability, and heterogeneous patient populations, posing challenges in

demonstrating safety and efficacy to regulatory authorities (Gieber et al., 2023). Additionally, the emergence of personalized medicine and biomarker-driven approaches introduces complexity into trial design and endpoint selection, requiring innovative methodologies to capture treatment effects accurately (Serelli-Lee et al., 2022).

The development of engineered tissues and advanced therapies presents unique challenges in regulatory approval due to the need for novel evaluation criteria and adaptive regulatory frameworks. Regulatory agencies must balance the need for rigorous scientific assessment with the urgency of bringing innovative therapies to market (Khalil et al., 2020). For example, the FDA's adaptive pathways approach, which allows for iterative evaluation of clinical data, aims to address these uncertainties by incorporating real-world evidence and post-approval studies (Teixeira et al., 2020).

Furthermore, scientific uncertainties often extend into the post-approval phase, requiring ongoing surveillance and data collection to ensure long-term safety and efficacy. This aspect is crucial for advanced therapies, where long-term effects may not be fully understood at the time of approval (Gomes et al., 2023).

2.2.4 Market Access and Economic Considerations

Market access considerations represent another significant challenge for pharmaceutical companies seeking approval for new drugs. The increasing emphasis on value-based healthcare and cost-effectiveness analyses has heightened the scrutiny on drug pricing and reimbursement decisions, creating additional barriers to market entry for innovative therapies (Cutler et al., 2020). Moreover, disparities in healthcare infrastructure and resource allocation among countries contribute to inequalities in access to medicines, highlighting the challenge of ensuring equitable distribution of new treatments ((Cortes et al., 2020); (Wouters et al., 2021)).

Pharmaceutical companies must navigate complex pricing and reimbursement landscapes to ensure that new therapies are accessible to patients while maintaining financial sustainability. Strategic market access planning and stakeholder engagement are essential to facilitate timely reimbursement and market uptake (Makurvet, 2021). The economic challenges are further compounded by the high cost of drug development, with estimates suggesting that bringing a new drug to market can cost over $2 billion (Cutler et al., 2020).

Additionally, the financial risks associated with drug development, including the high cost of clinical trials and the uncertainty of market success, necessitate strategic investments and partnerships. Companies often engage in collaborative agreements with other pharmaceutical firms, academic institutions, and research organizations to share the financial burden and leverage collective expertise (Lee et al., 2019).



***Figure 4: Proportion of drug development costs* (CBO, 2021; Sertkaya and Franz, 2022)**

2.2.5 Ethical and Operational Challenges

Ethical considerations also play a critical role in the drug approval process. Ensuring patient safety, obtaining informed consent, and maintaining data integrity are paramount in clinical trials. The dynamics of clinical research ethics and the potential for social desirability bias in patient-reported outcomes can impact the validity of clinical trial data (Ried et al., 2022). Additionally, operational challenges, such as implementing centralized Institutional Review Boards (IRBs) and ensuring consistent regulatory compliance across multicentre trials, add layers of complexity to the approval process (Burr et al., 2019).

The ethical complexities are particularly evident in global clinical trials, where varying standards for informed consent and patient protection can lead to ethical dilemmas. For example, a study by (Baumfeld Andre et al., 2020) highlights the ethical and operational challenges in conducting multinational trials, emphasizing the need for harmonized ethical guidelines and robust oversight mechanisms.

Operational challenges also include logistical issues, such as patient recruitment, retention, and data management. Ensuring the integrity of data collected from diverse sites and maintaining compliance with regulatory standards across different jurisdictions require robust infrastructure and coordination (Chiu et al., 2022).

Challenge type	Description
Ethical Challenges	Informed Consent, Data Integrity
Operational Challenges	Centralized IRBs, Patient Recruitment

Table 4: Ethical and Operational Challenges in Global Trials (Olopade et al., 2012)

2.2.6 Global Disparities and Access to Oncology Drugs

The global disparities in access to oncology drugs further illustrate the challenges in the drug approval process. Regulatory and operational barriers, such as differing evidentiary

standards and market access requirements, hinder the timely availability of innovative cancer therapies to patients worldwide (Barrios et al., 2023). Efforts to harmonize regulatory standards and streamline approval pathways are essential to address these disparities and improve global access to life-saving treatments (Epps et al., 2022).

A global comparative study on the access to oncology drugs underscores the disparities in drug availability, with patients in high-income countries having significantly better access to novel therapies compared to those in low- and middle-income countries (Barrios et al., 2023). This disparity is driven by factors such as regulatory approval timelines, pricing policies, and healthcare infrastructure.

Furthermore, the variability in regulatory requirements for oncology drugs can lead to delays in patient access to new treatments. Streamlining regulatory processes and promoting international collaboration are critical to addressing these disparities and ensuring that patients worldwide can benefit from advancements in cancer treatment (Cortes et al., 2020).



Figure 5: Access to Oncology Drugs by Income level **(Fundytus *et al.*, 2021)**

2.2.7 Case Study: Regulatory Challenges in COVID-19 Vaccine Approval

The COVID-19 pandemic highlighted the need for regulatory agility and collaboration among global regulatory authorities. The rapid development and approval of COVID-19 vaccines demonstrated the potential for expedited regulatory pathways and real-time data sharing to accelerate the availability of critical therapies (Cavaleri et al., 2021). However, the pandemic also underscored the challenges of balancing rigorous scientific evaluation with the urgency of public health crises (Wouters et al., 2021).

The FDA's accelerated approval of aducanumab for Alzheimer's disease further exemplifies the regulatory challenges and controversies surrounding the approval of high-impact therapies. The decision sparked debate over the adequacy of clinical evidence and the balance between innovation and patient safety (Wang, 2023). The approval process for COVID-19 vaccines, involving unprecedented collaboration and data transparency,

serves as a model for future regulatory practices but also highlights the need for continuous improvement in regulatory frameworks to address emerging public health threats (Cavaleri et al., 2021).

Moreover, the pandemic experience has prompted regulatory agencies to reconsider and adapt their approaches to emergency use authorizations (EUA) and accelerated approval pathways, emphasizing the importance of preparedness for future health emergencies (Skydel et al., 2022).

2.3 Organizational Strategies for Regulatory Approval

2.3.1 Introduction

Pharmaceutical organizations face significant challenges in navigating the regulatory approval processes for new drugs. To overcome these hurdles, companies employ various strategies aimed at expediting approval timelines, ensuring compliance with regulatory standards, and facilitating timely access to innovative therapies for patients. This section explores the organizational strategies utilized by pharmaceutical companies to address regulatory challenges and optimize the approval process.

2.3.2 Centralized Regulatory Pathways

Centralized regulatory pathways offer a streamlined approach for drug approval by consolidating the review process within a single regulatory authority. In the EU, the centralized procedure allows companies to submit a single marketing authorization application to the EMA, resulting in a single approval valid across all EU member states. This pathway is particularly beneficial for therapies addressing unmet medical needs or rare diseases (Franco et al., 2023). Similarly, the FDA's priority review designation in the USA accelerates the review process for drugs that provide significant improvements in treatment or address serious conditions (da Costa Gonçalves et al., 2022).



Figure 6: Percentage of Drugs Approved via Centralized Pathways **(Shizuya and Miyazaki, 2022)**

Centralized pathways leverage harmonized regulatory standards and collaborative decision-making processes to expedite drug approval. For instance, the EMA's accelerated assessment procedure reduces the review timeline from 210 days to 150 days, facilitating faster market entry for innovative therapies (Detela and Lodge, 2019). By adopting centralized regulatory pathways, pharmaceutical companies can navigate the approval process more efficiently and bring new treatments to patients more quickly.

2.3.4 Orphan Drug Designations

Orphan drug designations represent another key strategy employed by pharmaceutical companies to accelerate approval and market access for their products. These designations provide incentives, such as market exclusivity, protocol assistance, and fee waivers, to encourage the development of treatments for rare diseases with limited treatment options. The Orphan Drug Act in the USA and the Orphan Medicinal Products Regulation in the EU have been instrumental in promoting the development of orphan drugs (Baran-Kooiker et al., 2019).

By designating a drug as an orphan product, developers gain access to regulatory support and expedited review processes. For example, the FDA's orphan drug designation provides seven years of market exclusivity upon approval, along with tax credits and grant funding to support clinical development (Baran-Kooiker et al., 2019). These incentives not only reduce the financial burden on companies but also facilitate faster approval and patient access to life-saving therapies.

2.3.5 Expedited Review Programs

Expedited review programs are designed to accelerate the regulatory approval process for therapies addressing significant unmet medical needs. Programs such as the FDA's breakthrough therapy designation and the EMA's PRIME scheme offer enhanced regulatory support and expedited review timelines for drugs demonstrating substantial improvements over existing treatments (Eichler et al., 2019).

The breakthrough therapy designation, for instance, provides intensive guidance on drug development, involving senior FDA officials early in the review process to expedite development and review (Eichler et al., 2019). Similarly, the PRIME scheme offers early and proactive support to optimize drug development plans and enable accelerated assessment once a marketing authorization application is submitted (Franco et al., 2023). These programs facilitate closer collaboration between regulatory authorities and pharmaceutical companies, ensuring that innovative therapies reach patients more rapidly.

2.3.6 Adaptive Pathways and Real-World Evidence

Adaptive pathways represent a flexible approach to drug development and approval, allowing for iterative evaluation of clinical data and real-world evidence. This approach is particularly useful for therapies addressing unmet medical needs, where traditional clinical trial designs may be impractical or insufficient. Adaptive pathways enable early patient access to innovative treatments while gathering additional evidence to confirm the therapy's benefit-risk profile (Teixeira et al., 2020).



***Figure 7: Percentage of Drugs Approved Using Real-World Evidence* (Purpura *et al.*, 2022; Nishioka *et al.*, 2022; Bakker *et al.*, 2023)**

The use of RWE is increasingly recognized as a valuable tool in the regulatory decision-making process. RWE is derived from real-world data (RWD) collected from sources such as electronic health records, insurance claims, and patient registries. This evidence provides insights into how therapies perform in real-world settings, complementing clinical trial data and supporting regulatory approval (Dagenais et al., 2022). The FDA's Real-World Evidence Program and the EMA's Adaptive Pathways pilot project are examples of initiatives that incorporate RWE to facilitate regulatory decision-making and accelerate the approval process (Rouse et al., 2018).

2.3.7 Strategic Stakeholder Engagement

Effective stakeholder engagement is crucial for navigating the regulatory landscape and ensuring successful drug approval. Pharmaceutical companies must engage with a wide range of stakeholders, including regulatory authorities, healthcare providers, patient advocacy groups, and policymakers. This engagement facilitates a better understanding of regulatory expectations, promotes transparency, and builds trust among stakeholders (Mulberg et al., 2019).

Collaborative initiatives, such as public-private partnerships and multi-stakeholder consortia, play a pivotal role in addressing regulatory challenges and advancing innovative therapies. For example, the Innovative Medicines Initiative (IMI) in the EU brings together industry, academia, and regulatory bodies to develop solutions for pressing healthcare challenges, including regulatory science (Perehudoff et al., 2021). By fostering collaboration and knowledge-sharing, these initiatives help to streamline the drug development and approval process.

Stakeholder Type	Role and Importance
Regulatory Authorities	Ensure compliance with regulatory standards

Healthcare Providers	Provide clinical expertise and patient perspectives
Patient Advocacy Groups	Represent patient interests and needs
Policymakers	Influence regulatory policies and funding decisions
Pharmaceutical Companies	Develop and submit drug applications
External Experts / Consultants	Offer specialized knowledge and strategic advice

Table 5: Stakeholder roles in the Drug Approval Process (Hoos et al., 2015; Saesen et al., 2020)

2.3.7 Market Access and Pricing Strategies

Market access and pricing strategies are essential components of a comprehensive regulatory strategy. Pharmaceutical companies must navigate complex pricing and reimbursement landscapes to ensure that new therapies are accessible to patients while maintaining financial sustainability. Value-based pricing models, which link the price of a drug to its clinical benefits and outcomes, are increasingly being adopted to address these challenges (Gonçalves, 2022).

Negotiating with payers and healthcare systems to secure reimbursement for new therapies is a critical step in ensuring market access. Early engagement with health technology assessment (HTA) bodies and payers can help to align clinical development programs with market access requirements, facilitating smoother approval and uptake (Ofori-Asenso et al., 2020). Additionally, managed entry agreements and risk-sharing arrangements can provide flexible solutions for introducing new therapies while addressing payer concerns about budget impact and clinical uncertainty (Epps et al., 2022).

Strategy	**Description**
Value-Based Pricing	Links drug price to clinical benefits and outcomes
Early Engagement with HTA	Aligns development programs with market access requirements
Managed Entry Agreements	Provides flexible solutions for introducing new therapies
Risk-Sharing Agreements	Addresses payer concerns about budget impact and clinical uncertainty

Table 6: Market Access and Pricing Strategies (Siegal and Shah, 2019; Lawlor et al., 2021; Xoxi et al., 2022)

2.3.8 Case Study: Regulatory Strategies for Rare Diseases

The regulatory landscape for rare diseases presents unique challenges and opportunities. Rare diseases often lack effective treatments, creating a high unmet medical need. Regulatory initiatives such as the FDA's Rare Diseases Program and the EMA's Orphan Medicinal Products Regulation aim to address these challenges by providing targeted

support for the development and approval of therapies for rare diseases (Mulberg et al., 2019).

Pharmaceutical companies developing therapies for rare diseases can leverage expedited review programs, orphan drug designations, and adaptive pathways to accelerate the approval process. Additionally, the use of RWE and innovative trial designs, such as single-arm studies and basket trials (Renfro and Sargent, 2017), can help to generate robust evidence in small patient populations (Baran-Kooiker et al., 2019). By adopting a comprehensive regulatory strategy that integrates these elements, companies can overcome the unique hurdles associated with rare diseases and bring innovative treatments to patients in need.

2.4 Opportunities for Further Research

2.4.1 Introduction

While significant advancements have been made in the regulatory landscape and organizational strategies for drug approval, numerous opportunities for further research remain. These opportunities aim to enhance regulatory science, streamline approval processes, and improve patient access to innovative therapies. This section explores key areas where additional research can provide valuable insights and drive future developments in the field.

2.4.2 Comparative Analysis of Regulatory Frameworks

A comprehensive comparative analysis of regulatory frameworks across different ICH regions can provide valuable insights into the degree of regulatory convergence and divergence. By examining the similarities and differences in regulatory standards, approval timelines, and decision-making processes, researchers can identify best practices and areas for harmonization. This analysis can help to streamline global drug approval processes and reduce redundancies, ultimately facilitating faster access to new therapies for patients (Dhiman and Dureja, 2021).

Studies comparing regulatory outcomes, such as approval rates, review times, and post-marketing surveillance practices, can also shed light on the effectiveness of various regulatory approaches. For example, examining the impact of expedited review programs, like the FDA's breakthrough therapy designation and the EMA's PRIME scheme, on approval timelines and patient access can inform future regulatory policies and initiatives (Trapani et al., 2023). The newly added article by (Kumari et al., 2024) provides further insights into regulatory divergences, emphasizing the need for harmonized frameworks to facilitate global access to innovative therapies.

Regulatory Aspect	EMA	FDA	PMDA
Approval Timelines	Standard: ~210 days	Priority Review: ~6 months	Standard: ~12 months
Expedited Programs	PRIME, Accelerated Assessment	Breakthrough Therapy, Fast Track	Sakigake Designation
Post-Marketing Surveillance	Mandatory, extensive	Required, varies by drug	Required, ongoing
Real-World Evidence Utilization	Increasing focus	Emphasized	Increasing focus

Table 7: Key differences and similarities in regulatory standards, approval timelines, and decision-making processes across ICH regions (Jawahar and Datchayani, 2018; EMA, 2023; EMA, 2024b)

2.4.3 Real-World Evidence and Adaptive Pathways

The integration of real-world evidence (RWE) and adaptive pathways in the regulatory approval process presents significant opportunities for further research. RWE, derived from real-world data sources such as electronic health records and patient registries, can provide valuable insights into the safety and efficacy of therapies in real-world settings. Research focusing on the validation and utilization of RWE in regulatory decision-making can enhance the evidence base for new treatments and support more informed regulatory approvals (Cave et al., 2019).

Adaptive pathways, which allow for iterative evaluation of clinical data and early patient access, offer a flexible approach to drug development and approval. Investigating the implementation and outcomes of adaptive pathways can provide insights into their effectiveness in accelerating access to innovative therapies. Research can explore the challenges and benefits of adaptive pathways, as well as strategies for optimizing their use in regulatory processes (Teixeira et al., 2020).

Further, the article by (Gomes et al., 2023) discusses the post-marketing surveillance of advanced therapy medicinal products, highlighting the importance of continuous monitoring and adaptive pathways in ensuring long-term safety and efficacy.

Evaluating the impact of regulatory changes and policy interventions on drug approval timelines and patient access is crucial for continuous improvement in the regulatory landscape. Research can analyze trends in regulatory outcomes before and after the implementation of new regulations, such as the EU's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). By assessing the effectiveness of these changes, researchers can identify areas for further refinement and optimization (Stephenson et al., 2023).

Additionally, studies focusing on stakeholder perspectives, including those of regulators, industry stakeholders, and patient advocates, can provide valuable insights into the underlying factors driving regulatory decision-making and policy development. Engaging with these stakeholders can help to address challenges and opportunities associated with regulatory harmonization and expedited drug approval (Epps et al., 2022).

2.4.4 Development of Novel Regulatory Tools and Methodologies

The development and validation of novel regulatory tools and methodologies, such as real-world data generation and adaptive trial designs, can significantly enhance the efficiency and effectiveness of the drug approval process. Research in this area can explore the feasibility and impact of these innovative approaches, addressing current limitations and accelerating the translation of scientific discoveries into safe and effective therapies for patients (Subbiah, 2023).

For instance, investigating the use of real-world data to complement traditional clinical trial data can provide a more comprehensive understanding of a therapy's benefit-risk profile. Studies can also evaluate the potential of adaptive trial designs, which allow for modifications based on interim results, to optimize trial efficiency and increase the likelihood of successful approval (Mooghali et al., 2024).

2.4.5 Ethical Considerations in Regulatory Science

Ethical considerations play a critical role in regulatory science, particularly in the context of accelerated approval pathways and real-world evidence generation. Research can explore the ethical implications of these approaches, including issues related to patient safety, informed consent, and data privacy. By addressing these ethical concerns, researchers can ensure that regulatory practices uphold the highest standards of integrity and patient protection (Bahans et al., 2021).

Studies can also investigate the ethical challenges associated with the use of adaptive pathways and expedited review programs. For example, examining the balance between early patient access to innovative therapies and the need for robust evidence of safety and efficacy can provide insights into ethical decision-making in regulatory processes (Simpson et al., 2020).

Ethical Issue	Description	Mitigation Strategies
Patient Safety	Ensuring new treatments are safe	Rigorous monitoring, post-marketing studies
Informed Consent	Clear communication about risks and benefits	Transparent patient information, education
Data Privacy	Protecting patient data in real-world studies	Robust data protection protocols
Equity in Access	Ensuring all patients have access to new therapies	Policy interventions, global health initiatives

Table 8: Ethical Issues in Drug Approval and Corresponding Mitigation Strategies (Andreoletti and Blasimme, 2023; Djordjevic et al., 2023)

2.4.6 Global Health and Equity in Drug Access

Ensuring equitable access to innovative therapies on a global scale remains a significant challenge. Research can focus on identifying barriers to access and developing strategies to address disparities in healthcare infrastructure, economic development, and regulatory capacity across different regions. By promoting global health equity, researchers can contribute to more inclusive and effective regulatory frameworks (Cortes et al., 2020).

Studies can explore the impact of international collaborations and initiatives, such as the World Health Organization's (WHO) prequalification program and the Medicines Patent Pool, on improving access to essential medicines in low- and middle-income countries. Investigating the role of regulatory convergence and reliance in facilitating access to new therapies can also provide valuable insights for policymakers and regulatory authorities (Wouters et al., 2021).

2.5 Conclusion

The literature review provides a comprehensive analysis of the regulatory landscape, challenges in the drug approval process, organizational strategies for overcoming regulatory hurdles, and opportunities for further research. This conclusion synthesizes the key findings from each section and highlights areas for future exploration.

2.5.1 Summary of Key Findings

The regulatory landscape for drug approval is characterized by its complexity and ongoing efforts to harmonize standards across ICH regions. Despite these efforts, significant differences remain in the interpretation and application of scientific evidence, approval timelines, and decision-making processes among the EMA, the FDA, and PMDA. These variations can impact the timely availability of innovative therapies, underscoring the need for continued regulatory convergence.

Challenges in the drug approval process are multifaceted, involving the acceptance of clinical trial data, scientific uncertainties, and market access considerations. Regulatory authorities differ in their requirements for clinical evidence, trial designs, and statistical methodologies, which can lead to different outcomes in the approval process. Additionally, scientific uncertainties inherent in drug development and market access hurdles pose significant barriers to bringing new therapies to patients.

Organizational strategies to navigate these challenges include leveraging centralized regulatory pathways, orphan drug designations, and expedited review programs. These strategies have proven effective in streamlining the approval process and facilitating timely access to innovative therapies. However, their effectiveness varies across regions, necessitating tailored approaches that consider regional regulatory nuances.

2.5.2 Identified Gaps

The literature reveals several gaps that warrant further investigation. Key gaps include the need for more comprehensive studies on the harmonization of regulatory standards across ICH regions, the efficacy of adaptive pathways and RWE in regulatory decision-making, and the ethical implications of expedited review programs. Additionally, there is a need for research on global health equity to ensure equitable access to innovative therapies worldwide.

2.5.3 Implications for Future Research

Future research should focus on comparative analyses of regulatory frameworks to identify best practices and areas for harmonization. Studies exploring the integration of RWE and adaptive pathways in the regulatory process can enhance the evidence base for new treatments and support more informed regulatory approvals. Evaluating the impact of regulatory changes and policy interventions on approval timelines and patient access can inform future regulatory policies and initiatives.

Research should also investigate the development and validation of novel regulatory tools and methodologies, such as real-world data generation and adaptive trial designs, to enhance the efficiency and effectiveness of the drug approval process. Ethical considerations in regulatory science, particularly in the context of accelerated approval pathways and RWE generation, should be addressed to ensure patient safety and integrity in regulatory practices.

2.5.4 Linking to Research Objectives

This literature review supports the research objectives by providing a detailed understanding of the current regulatory landscape, identifying specific challenges faced by pharmaceutical organizations, examining effective organizational strategies, and highlighting areas for future research. The findings from this review will serve as a foundation for the subsequent primary research, guiding the development of evidence-

based recommendations to enhance the efficiency and effectiveness of regulatory approval processes for first-in-class drugs in ICH regions.

By addressing these opportunities, researchers can contribute to the optimization of regulatory processes, ultimately enhancing patient access to innovative and life-saving therapies. The insights gained from this review will inform the design and implementation of primary research, ensuring that the study addresses critical gaps and advances the field of regulatory science.

Chapter Three: Research Methodology

3.1 Introduction

The research methodology section outlines the approach and methods used to conduct this study, providing justification for the chosen methodology and detailing the specific design, data collection, and analysis techniques. This section also addresses potential ethical issues and describes how the data will be managed and stored. By establishing a clear and robust methodology, this research aims to ensure the validity and reliability of its findings.

3.2 Philosophical Approach

The philosophical approach underpinning this research is rooted in a positivist paradigm, which is appropriate given the aim to objectively measure and analyze the challenges faced by pharmaceutical organizations in obtaining regulatory approval in ICH regions. Positivism emphasizes the use of scientific methods to collect and analyze data, with the aim of producing reliable and generalizable findings (Park *et al.,* 2020) . This approach supports the research objectives by facilitating the collection of quantifiable data that can be subjected to statistical analysis, allowing for the identification of patterns and relationships within the data (Zyphur and Pierides, 2020).

Positivism aligns with the research objectives by providing a framework for empirical inquiry, focusing on observable phenomena that can be measured and analyzed quantitatively. This approach is particularly suitable for this study, which seeks to explore the regulatory challenges and strategies in the pharmaceutical industry, areas where objective measurement is critical (Mohajan, 2020). The use of structured surveys, a key component of the positivist approach, enables the collection of data in a systematic and replicable manner, ensuring that the findings are grounded in empirical evidence (Sürücü and Maslakçi, 2020).

Moreover, the positivist approach facilitates the use of hypothesis testing, allowing researchers to examine specific predictions about the relationships between variables. This methodical approach enhances the reliability of the findings, as it relies on the use of standardized instruments and statistical techniques to ensure objectivity and replicability (Neuert *et al.,* 2023). By adhering to the principles of positivism, this study aims to contribute to the broader body of knowledge in regulatory science through the generation of robust, evidence-based insights.

In addition to its emphasis on objectivity, the positivist approach also supports the goal of generalization (Hays and McKibben, 2021). By focusing on quantifiable data, this study can produce findings that are applicable across different contexts and settings within the pharmaceutical industry. This generalizability is crucial for developing recommendations that can be widely implemented, thereby enhancing the overall impact of the research.

3.3 Research Design

This study employs a quantitative research strategy using structured surveys to collect data. The survey is designed to gather detailed information on the experiences and perspectives of regulatory professionals working in pharmaceutical companies, specifically those involved in seeking regulatory approval for first-in-class drugs within ICH regions (EU, USA, and Japan). The quantitative approach is chosen to facilitate the

collection of data that can be statistically analyzed, allowing for generalizations to be made about the broader population of regulatory professionals.

The survey design includes a mix of closed-ended questions, which provide quantifiable data, and open-ended questions, which offer qualitative insights. This combination ensures a comprehensive understanding of the regulatory landscape, challenges, and strategies. The closed-ended questions use Likert scales, multiple-choice options, and ranking formats to capture participants' views in a structured manner, while the open-ended questions allow respondents to elaborate on specific challenges and strategies in their own words (Neuert *et al.,* 2023).

The choice of a mixed-methods survey design is strategic, as it allows for the integration of both quantitative and qualitative data (Åkerblad *et al.,* 2021). This approach provides a more nuanced understanding of the research problem by capturing the depth and complexity of respondents' experiences and perspectives (Ozuem *et al.,* 2022). Additionally, the inclusion of open-ended questions helps to uncover insights that may not be captured through closed-ended questions alone, thereby enriching the overall data set.

Furthermore, the survey will be designed to minimize potential biases and ensure the reliability of the responses. This includes using clear and neutral language in the questions, randomizing the order of response options to prevent order effects, and providing instructions to help respondents understand the questions and response options (Kmetty and Stefkovics, 2022). By implementing these design considerations, the survey aims to produce accurate and reliable data that can inform meaningful conclusions and recommendations.

3.4 Survey Development and Testing

The survey consists of 17 questions, including closed-ended questions to capture quantitative data and open-ended questions to gather qualitative insights. The questions cover participant demographics, the global regulatory landscape, specific approval challenges, organizational strategies, and recommendations for improvement. Before distribution, the survey was tested with a small group of regulatory professionals to identify and rectify any issues with question clarity and survey logic. This pilot testing ensured that the questions were understandable and relevant to the target population.

Feedback from the pilot testing phase was used to refine the survey questions, ensuring that they effectively captured the necessary data without causing confusion or ambiguity. Adjustments were made to improve the wording of questions, the structure of the survey, and the response options provided. This iterative process helped to enhance the reliability and validity of the survey instrument.

3.5 Participant Recruitment

Participants will be recruited primarily through LinkedIn and professional networks, targeting regulatory professionals working in pharmaceutical companies, biotech firms, Contract Research Organizations (CRO), and regulatory consultancies who have experience with regulatory submissions for first-in-class drugs. A purposive sampling technique ensures that participants meet specific criteria, including current employment in a relevant organization and experience with regulatory submissions in at least one ICH region.

3.5.1 Inclusion Criteria

- Participants must be currently employed in a pharmaceutical company, biotech firm, CRO, or regulatory consultancy.
- Participants must have experience with regulatory submissions in at least one ICH region (EU, US, Japan).

3.5.2 Exclusion Criteria

- Participants not currently employed in a relevant organization (pharmaceutical company, biotech firm, CRO, or regulatory consultancy).
- Participants without experience in regulatory submissions within ICH regions.

To maximize participation, the recruitment process will involve personalized invitations and follow-up reminders. LinkedIn will be used to identify potential participants based on their professional profiles, and connections will be leveraged to facilitate introductions and endorsements. Additionally, industry forums, professional associations, and conferences will be used to promote the survey and encourage participation. These efforts aim to ensure a diverse and representative sample of regulatory professionals, enhancing the generalizability of the findings.

3.5.3 Sample Size and Calculation

The sample size was calculated using the following formula for a proportion in a finite population:

$n = N * [Z^2 * p * (1-p)/e^2] / [N – 1 + (Z^2 * p * (1-p)/e^2]$ (Wallstreetmojo, 2019)

- n = sample size
- N = population size (124,436 regulatory professionals globally (RAPS, 2024))
- z = z-value (1.96 for a 95% confidence level)
- p = estimated proportion of regulatory professionals with relevant experience (assumed to be 0.5 for maximum variability)
- e = margin of error (0.1 or 10%)

Therefore, a sample size of approximately 96 participants is targeted to achieve a 95% confidence level with a 10% margin of error.

3.5.4 Risks of Not Hitting the Target

Failing to achieve the target sample size may affect the generalizability and statistical power of the study. A smaller sample size may not adequately represent the population, leading to biased results. Additionally, the ability to detect significant differences or relationships within the data may be compromised. To mitigate these risks, multiple recruitment strategies will be employed, including leveraging professional networks, using targeted outreach on LinkedIn, and promoting the survey through industry forums and professional associations.

3.6 Data Collection

The survey will be distributed electronically, allowing for a wide reach and facilitating the participation of regulatory professionals across various geographical locations. Participants will be invited to complete the survey via a link sent through email or LinkedIn messages. The electronic format ensures convenience for participants, enabling them to complete the survey at their own pace and from any location.

The data collection period will span several weeks to allow ample time for participants to respond. Regular reminders will be sent to non-respondents to encourage participation and improve response rates. The survey platform will be designed to ensure data security and confidentiality, with responses stored in a secure, password-protected database.

3.7 Data Analysis

Quantitative data from the survey will be analyzed using descriptive statistics, including frequencies, percentages, means, and standard deviations (Mishra *et al.,* 2019). This analysis will be conducted using Microsoft Excel, which is accessible and sufficient for this level of analysis. The results will be presented using tables, charts, and graphs to facilitate interpretation and highlight key findings.

Descriptive statistics will provide an overview of the demographic characteristics of the participants, their experiences with regulatory approval processes, and their perceptions of the challenges and strategies involved. Inferential statistical techniques, such as chi-square tests, ANOVA and t tests, will be employed using Statistical Product and Service Solutions (SPSS) software to explore relationships between variables and identify significant differences between groups.

For qualitative data from open-ended survey responses, thematic analysis will be employed to identify common themes and insights related to the research objectives. This process involves coding the responses to group similar concepts and ideas, allowing for a structured and systematic examination of the data (Braun and Clarke, 2022). The findings from this analysis will be summarized and presented in a narrative format, supported by quotes from participants to provide context and depth to the themes identified.

The combination of quantitative and qualitative data analysis techniques will provide a comprehensive understanding of the challenges faced by pharmaceutical organizations in obtaining regulatory approval in ICH regions. This mixed-methods approach ensures that both numerical data and detailed personal insights are captured, offering a richer and more nuanced perspective on the research questions (Wallwey and Kaifez, 2023) .

3.8 Ethical Considerations

Ethical considerations are paramount in this research, particularly given the involvement of human participants. The study will ensure informed consent is obtained from all participants, emphasizing voluntary participation and the right to withdraw at any stage without repercussions. Confidentiality of responses will be strictly maintained through anonymization and secure data storage practices. Data will be stored on a password-protected laptop, and backed up regularly to a secure back up drive both of which will be kept in a locked cabinet at the researcher's residence. This data will be uploaded to Griffith College as part of the thesis submission and stored for a minimum of two years after the completion of the research.

Potential biases, such as social desirability bias or conflicts of interest, will be mitigated through transparency and rigorous data validation procedures (Ried *et al.,* 2022). Efforts will be made to minimize risks to participants, prioritizing their well-being throughout the research process. Any uncertainties or difficulties encountered will be promptly addressed through proactive measures, ensuring ethical compliance and integrity in research conduct.

3.9 Addressing Potential Challenges

One potential challenge in this research is obtaining a sufficiently large sample size of regulatory professionals, given the specific expertise required. To mitigate this, the researcher will leverage professional networks, including LinkedIn and current work colleagues, to maximize reach and participation. Additionally, the survey has been designed to ensure it is not overly time-consuming, encouraging higher response rates.

Another challenge is the potential variability in the regulatory experiences of participants across different ICH regions. To address this, the survey includes questions tailored to capture region-specific insights and challenges. This approach ensures that the data collected reflects the diverse regulatory landscapes of the EU, USA, and Japan, providing a comprehensive understanding of the global regulatory environment.

A further challenge is the potential for response bias, particularly social desirability bias, where respondents may provide answers, they perceive as favourable or expected rather than their true experiences. To minimize this, the survey will be anonymous, encouraging participants to provide honest and candid responses without fear of identification or repercussions. Clear instructions and assurances of confidentiality will be provided to all participants, emphasizing the importance of their truthful input for the validity of the research.

3.10 Justification of Methodological Approach

The chosen methodological approach is justified by the need for objectivity and the ability to generalize findings across the broader pharmaceutical industry. By employing a positivist paradigm and a quantitative research strategy, this study aims to produce empirical, generalizable knowledge about the regulatory challenges in the pharmaceutical industry. The use of structured surveys minimizes bias and ensures that the data collected is reliable and valid (Story and Tait, 2019). Furthermore, statistical analysis techniques will enable the researcher to draw meaningful conclusions and make evidence-based recommendations for improving regulatory approval processes in ICH regions.

The use of quantitative methods is particularly suitable for this study because it allows for the systematic collection and analysis of data from several respondents. This approach facilitates the identification of patterns and trends, enabling the researcher to make informed comparisons and generalizations. Additionally, the incorporation of qualitative elements through open-ended survey questions provides depth and context to the quantitative findings, enhancing the overall richness and comprehensiveness of the study.

The quantitative approach aligns with the positivist paradigm by focusing on measurable, observable phenomena and using statistical techniques to analyze the data. This ensures that the research findings are based on empirical evidence and can be generalized to the broader population of regulatory professionals. The use of structured surveys as a data

collection method supports the goal of obtaining reliable and consistent data, while the combination of quantitative and qualitative analysis techniques allows for a comprehensive examination of the research questions.

In terms of practical implications, the positivist approach and the use of quantitative methods provide a strong foundation for developing actionable recommendations (Aguinis *et al.,* 2020). The findings from this study can inform policy decisions and organizational practices within the pharmaceutical industry, thereby contributing to the optimization of regulatory processes and enhancing patient access to innovative therapies. By grounding these recommendations in empirical evidence, the study aims to ensure that they are both practical and effective in addressing the identified challenges.

Furthermore, the methodological approach adopted in this study is consistent with best practices in regulatory science research. The use of structured surveys and statistical analysis techniques aligns with established standards for conducting rigorous and reliable research in this field (Mellinger and Hanson, 2020). By adhering to these standards, the study aims to contribute to the broader body of knowledge in regulatory science and provide valuable insights that can inform future research and practice.

3.11 Data Management and Storage

The research data will be stored in a password-protected laptop that will be kept in a locked cabinet in the researcher's residence. The laptop and secure backup device will only be accessible by the researcher. The data will be stored for a minimum of two years after the completion of the research, in accordance with institutional guidelines. No personal information will be collected, and only necessary information pertaining to the research will be gathered. The data will be anonymized to protect the identities of participants and ensure confidentiality.

Data management practices will adhere to best practices for data security and integrity. This includes regular backups of the data to prevent loss, encryption of sensitive information, and secure deletion of data after the retention period has ended. The researcher will also ensure compliance with any relevant data protection regulations and guidelines, such as the General Data Protection Regulation (GDPR), to safeguard the privacy and rights of participants.

3.12 Conclusion

This chapter has detailed the research methodology used in this study, providing justification for the chosen philosophical approach, research design, and data collection methods. By addressing these methodological aspects, the research aims to produce valuable insights into the regulatory challenges in the pharmaceutical industry and contribute to the optimization of regulatory processes. The detailed and systematic approach outlined in this chapter provides a solid foundation for the subsequent data collection and analysis, ensuring that the research is conducted rigorously and ethically.

By employing a positivist paradigm and a quantitative research strategy, this study seeks to generate empirical, generalizable knowledge about the regulatory challenges faced by pharmaceutical organizations in ICH regions. The use of structured surveys, coupled with rigorous data analysis techniques, ensures that the findings are reliable and valid. Ethical considerations have been carefully addressed to protect the rights and well-being of participants, and potential challenges have been proactively mitigated to enhance the robustness of the research. The insights gained from this study will inform the

development of evidence-based recommendations for improving regulatory approval processes, ultimately enhancing patient access to innovative and life-saving therapies.

Chapter Four: Findings and Analysis

4.1 Introduction

This chapter presents the data gathered through a survey, analyzes the responses, and discusses the insights obtained. The findings are organized to reflect the structure of the survey, divided into sections on participant demographics and background, the global regulatory landscape, specific approval challenges, organizational strategies, and recommendations for improvements. The analysis is supported by visual aids to illustrate key points and trends. This chapter also compares and contrasts the primary research findings with those from the secondary research (literature review).

The purpose of this section is to provide a comprehensive understanding of the regulatory challenges and strategies in the pharmaceutical industry, particularly in relation to the accelerated approval of first-in-class drugs in ICH regions (EU, USA, Japan). By integrating both quantitative and qualitative data retrieved from the survey, this chapter aims to offer a holistic view of the current regulatory landscape, identify significant barriers faced by regulatory professionals, and highlight effective organizational strategies to navigate these challenges.

The data collected through the survey will be analyzed using various statistical techniques, including chi-square tests, t-tests and one way-ANOVA, to identify patterns and relationships within the data. Additionally, thematic analysis will be employed for qualitative responses to uncover deeper insights and contextual nuances. This multifaceted approach ensures that the findings are robust, reliable, and reflective of the diverse experiences and perspectives of regulatory professionals.

Moreover, this chapter aims to link the primary data with the theoretical framework and hypotheses established in the literature review. By doing so, it will validate the research hypotheses, explore any discrepancies, and provide evidence-based recommendations for improving the regulatory approval process for innovative therapies. The ultimate goal is to contribute valuable insights to the regulatory and pharmaceutical community, facilitating the development of more efficient and effective regulatory pathways.

4.2 Participant Demographics and Background

Understanding the demographics and background of the survey participants is crucial for contextualizing the findings (Lett et al., 2022). This section provides an overview of the respondents' job titles, years of experience in regulatory affairs, the ICH regions they primarily work in, and the types of organizations they represent. The survey included responses from 99 participants, ensuring a diverse and comprehensive representation of regulatory professionals. This demographic data helps to ensure that the survey results are interpreted accurately and that any patterns or trends identified are representative of the wider population of regulatory professionals.

In determining the sample size for this study, a margin of error of 10% was selected. This decision was based on several factors:

1. **Exploratory Nature of the Study:** This research aims to explore and identify key trends and patterns in the regulatory approval process for first-in-class drugs, rather than making precise estimates. As such, a larger margin of error is acceptable for capturing broad insights.

2. **Population Size:** The global population of regulatory professionals is approximately 124,436 (RAPS, 2024). Given this large population, achieving a smaller margin of error, such as 5%, would require a significantly larger sample size, which is not feasible within the study's constraints.
3. **Resource Constraints:** Considering the limited time and resources available for this study, a 10% margin of error strikes a balance between accuracy and practicality. This margin allows for a sample size that is manageable within the given constraints while still providing meaningful insights.
4. **Confidence Level:** With a 95% confidence level, the 10% margin of error indicates that we can be 95% confident that the true population parameter lies within ±10 percentage points of the sample estimate. This level of precision is deemed sufficient for the purposes of this exploratory study (SurveyMonkey, 2024).

By using a 10% margin of error, this study ensures that the findings are both reliable and achievable within the given resources, while still providing valuable insights into the regulatory approval processes.

4.2.1 Years of Experience in Regulatory Affairs

Participants reported a wide range of experience levels in regulatory affairs, which is indicative of the diversity in professional backgrounds and expertise. The distribution is as follows:



Figure 8: Regulatory experience level by participant

4.2.2 Primary ICH Regions

The primary regions where respondents work is distributed as follows:



Figure 9: Distribution of regulatory experience working with which region

This distribution highlights the focus of the survey on the major ICH regions, with a significant proportion of participants working primarily in the EU, followed by the US. The absence of respondents working in the Japanese region suggests a potential area for future research to include a more representative sample from all ICH regions.

Cross analysis between years of experience and primary ICH region

To understand if there is a relationship between the years of experience in regulatory affairs and the primary ICH regions where participants work, a Chi-Square Test was conducted. The results are as follows:

Chi-Square test

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	21.126[a]	16	.174
Likelihood Ratio	20.309	16	.207
Linear-by-Linear Association	0.365	1	.546
N of Valid Cases	99		

Table 9: Chi Square test for years of experience vs ICH regions familiarity amongst participants

* a. 19 cells (76.0%) have expected count less than 5. The minimum expected count is .09.

Interpretation of Results:

The Chi-Square test results (χ^2 = 21.126, df = 16, p = .174) indicate no statistically significant relationship between years of experience and primary ICH region. This

suggests that participants' experience levels are evenly distributed across different regulatory regions.

Key Observations:

1. **No Significant Association:**

- The results suggest that the years of experience in regulatory affairs do not significantly differ across the primary ICH regions where the participants work.

2. **Distribution of Experience:**

- The lack of a significant association implies that regulatory professionals with varying years of experience are relatively evenly distributed across the different ICH regions.

Further Analysis and Discussion:

While the Chi-Square Test indicates no significant relationship between years of experience and primary ICH regions, it's important to consider the practical implications:

1. **Experience Distribution:**

- This finding suggests that the regulatory affairs field in different ICH regions is not dominated by professionals with a specific range of experience. This could imply a balanced mix of novice, mid-level, and experienced professionals across the regions.

2. **Implications for Training and Development:**

- Organizations operating in different ICH regions might benefit from standardized training and development programs that cater to regulatory professionals at all experience levels, given the evenly distributed experience levels.

Limitations and Further Research:

- The analysis is based on responses from 99 participants. Future research could involve a larger sample size to validate these findings.
- In summary, the Chi-Square analysis suggests no significant association between years of experience and the primary ICH regions, indicating a balanced distribution of experience levels across regions. This highlights the potential for universal strategies in regulatory training and development, benefiting the global regulatory affairs community.

4.2.3 Type of Organization

Respondents work in a variety of organizational settings, reflecting the diverse landscape of the pharmaceutical and regulatory industry. The types of organizations represented by participants are as follows:



Figure 10: Organization type by participant

This diverse organizational representation ensures that the findings of the survey are relevant to different types of companies within the industry, from large pharmaceutical firms to specialized regulatory consultancies.

To further explore potential differences between Biopharma and Non-Biopharma organizations specifically, a series of statistical tests were conducted, including a Chi-Square test, an Independent Samples t-Test, and an ANOVA.

Chi-Square test

Test Type	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	4.893	4	.298
Likelihood Ratio	5.957	4	.202
Linear-by-Linear Association	1.197	1	.274
N of valid cases	99		

Table 10: Chi Square test for association between the type of organization (Biopharma vs. Non-Biopharma) and the perceived complexity of regulatory requirements

A Chi-Square test was performed to examine the association between the type of organization (Biopharma vs. Non-Biopharma) and the perceived complexity of regulatory requirements. The results of the Chi-Square test ($\chi^2(4) = 4.893$, $p = .298$) indicate that there is no statistically significant association between the type of organization and the perceived complexity of regulatory requirements. This suggests that the type of organization (whether Biopharma or Non-Biopharma) does not significantly influence how complex respondents perceive the regulatory requirements to be.

Independent Samples t-Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						95% Confidence Interval of the Difference	
Test Type	**Value**	**F**	**Sig.**	**t**	**df**	**One-Sided p**	**Two-Sided p**	**Mean Difference**	**Std. Error Difference**	**Lower**	**Upper**
Biopharmaceutical company	Equal variances assumed	0.067	.797	.254	49	.400	.801	.09184	.36197	-.63557	.81925
Non-Biopharmaceutical company	Equal variances not assumed			.182	1.041	.442	.885	.09184	.50501	-5.76176	5.94544

Table 11: Independent Samples t-Test to compare the mean responses of Biopharma and Non-Biopharma organizations regarding their overall engagement with regulatory agencies

An Independent Samples t-Test was conducted to compare the mean responses of Biopharma and Non-Biopharma organizations regarding their overall engagement with regulatory agencies. The results (t(49) = .254, p = .801) reveal no significant difference in the engagement levels between Biopharma and Non-Biopharma organizations. This finding suggests that regardless of the organizational type, the frequency and manner of engagement with regulatory agencies are relatively consistent across the industry.

ANOVA

ANOVA	**Sum of Squares**	**df**	**Mean Square**	**F**	**Sig.**
Between Groups	.018	1	.018	.028	.867
Within Groups	61.821	97	.637		
Total	61.838	98			

Table 12: ANOVA to assess differences in the perceived significance of clinical and evidentiary hurdles in delaying the approval of innovative treatments between Biopharma and Non-Biopharma organizations

An ANOVA was performed to assess whether there are differences in the perceived significance of clinical and evidentiary hurdles in delaying the approval of innovative

treatments between Biopharma and Non-Biopharma organizations. The results ($F(1, 97) = .028$, $p = .867$) indicate no significant difference in the perceived significance of these hurdles across the two types of organizations. This further supports the notion that both Biopharma and Non-Biopharma organizations face similar challenges in the approval process, and their perception of these challenges does not vary significantly.

Conclusion

The statistical analyses conducted suggest that there are no significant differences between Biopharma and Non-Biopharma organizations concerning their engagement with regulatory agencies, their perception of clinical and evidentiary hurdles, or their perception of the complexity of regulatory requirements. This finding is insightful, as it implies a level of uniformity in how different types of organizations approach regulatory challenges, despite their diverse backgrounds and operations. It underscores the idea that the regulatory landscape imposes similar demands and challenges across the pharmaceutical industry, regardless of the specific organizational context.

4.3 Global Regulatory Landscape

This section explores the participants' familiarity with different regulatory frameworks and their perceptions of the complexity of regulatory requirements in their regions. Understanding these perceptions is crucial for identifying areas where regulatory processes might be streamlined or improved (Dombeck *et al.*, 2022).

4.3.1 Familiarity with Regulatory Frameworks

Participants indicated their familiarity with various regulatory frameworks, reflecting the breadth of their professional experience and the global nature of regulatory affairs.

The dominance of familiarity with EMA and FDA frameworks underscores the prominence of these regions in global pharmaceutical regulations. The absence of familiarity with PMDA (Japan) is notable and suggests a gap in experience or a potential participant constraint, geographically. This distribution can be cross-analyzed with the regions where participants primarily work to understand how professional experience aligns with regulatory familiarity. The distribution is as follows:



Figure 11: Familiarity with regulatory framework by region

4.3.2 Complexity of Regulatory Requirements

Participants rated the complexity of regulatory requirements for first-in-class drugs in their regions. The distribution is as follows:



Figure 12: Complexity of the regulatory requirements for first-in-class drugs by participant region

This distribution indicates that a significant majority of respondents find the regulatory requirements to be moderate or complex.

4.3.3 Differences in Regulatory Requirements

Participants provided insightful comments on the differences in regulatory requirements across ICH regions. Several key themes emerged from these responses, highlighting the challenges and variations faced by regulatory professionals.

Variations in Documentation and Clinical Trial Requirements

One of the predominant themes was the variation in documentation and clinical trial requirements among the ICH regions. Respondents noted that while the EMA, FDA, and PMDA all aim to ensure the safety and efficacy of new drugs, the specifics of their requirements can differ significantly.

For instance, participants working within the EU emphasized that the EMA requires comprehensive documentation that aligns with the centralized procedure, including detailed clinical trial data and extensive pharmacovigilance plans. In contrast, the FDA's approach, while rigorous, allows for more flexibility in the design of clinical trials, often accepting surrogate endpoints and adaptive trial designs. This flexibility can sometimes expedite the approval process but also introduces variability in the type and amount of data required.

Differences in Approval Timelines and Decision-Making Processes

Another critical theme was the difference in approval timelines and decision-making processes. Respondents highlighted that the FDA's expedited programs, such as Fast Track and Breakthrough Therapy Designations, often result in faster approval times compared to the EMA's centralized procedure. However, this speed can come at the cost of requiring extensive post-marketing studies to confirm the initial findings.

In Japan, the PMDA's review process was noted for its collaborative nature, particularly through initiatives like the Sakigake Designation, which emphasizes early and continuous dialogue between the regulator and the applicant. This collaborative approach can lead to a more streamlined approval process but requires significant upfront engagement and ongoing communication (Franco *et al.*, 2023).

Divergence in Data Quality Expectations and Evidence Standards

A theme that emerged strongly was the divergence in data quality expectations and evidence standards. Participants pointed out that the EMA often places a higher emphasis on the quality and robustness of clinical data, particularly focusing on added therapeutic value over existing treatments. This approach ensures that new therapies provide significant benefits to patients but can create hurdles for companies trying to meet these high standards.

Conversely, the FDA's acceptance of real-world evidence and surrogate endpoints was seen as both an advantage and a challenge. While it allows for quicker approvals, it also raises questions about the long-term efficacy and safety of approved drugs (Ciani *et al.*, 2023). The PMDA's growing focus on real-world evidence is similarly seen as a double-edged sword, facilitating quicker approvals but requiring rigorous post-marketing surveillance to ensure ongoing safety and efficacy.

Regional Focus and Priorities

Participants also discussed how regional focus and priorities impact regulatory requirements. The EMA's guidelines are often influenced by the EU's broader public health policies, which prioritize access to affordable medicines and the management of public health emergencies (Horgan and Kent, 2017) . The FDA, operating within the US healthcare system, places a strong emphasis on innovation and rapid access to cutting-edge therapies, which can lead to a different set of regulatory priorities (Gotlieb, 2018).

In Japan, the PMDA's regulatory framework is heavily influenced by the country's commitment to rapid innovation and its unique healthcare challenges. The focus on advanced therapies, such as regenerative medicine and gene therapy, reflects Japan's strategic priorities and impacts the regulatory pathways available to companies (Shimura, 2022).

Summary

The thematic analysis of respondents' comments reveals a complex and nuanced landscape of regulatory requirements across ICH regions. The key themes of documentation and clinical trial requirements, approval timelines and decision-making processes, data quality expectations and evidence standards, and regional focus and priorities illustrate the diverse challenges faced by regulatory professionals. These insights provide a deeper understanding of the regulatory environment and underscore the importance of tailored strategies to navigate these regional differences effectively.

4.3.4 Engagement with Regulatory Agencies

The frequency of engagement with regulatory agencies during the approval process is as follows:



Figure 13: Level of engagement with regulatory agencies during approval process

Cross-Analysis of Perceived Complexity of Regulatory Environment and Engagement with Regulatory Agencies:

To explore the relationship between participants' perceptions of the complexity of the regulatory environment and their frequency of engagement with regulatory agencies, a Chi-Square test was conducted. The results are as follows:

Chi-Square Test

Test Type	Value	df	Asymptotic Significance (2-sided)

Pearson Chi-Square	22.619	16	.125
Likelihood Ratio	19.397	16	.249
Linear-by-Linear Association	1.997	1	.158
N of valid cases	99		

Table 13: Chi Square test for participants' perceptions of the complexity of the regulatory environment and their frequency of engagement with regulatory agencies

Interpretation of Results:

The Pearson Chi-Square value is 22.591 with 16 degrees of freedom and a p-value of .125. This p-value is greater than the conventional threshold of .05 (Andrade, 2019), indicating that there is no statistically significant association between the perceived complexity of the regulatory environment and the frequency of engagement with regulatory agencies among the respondents .

Key Observations:

- The lack of a significant association suggests that the complexity of the regulatory environment, as perceived by participants, does not significantly influence how often they engage with regulatory agencies.
- The frequency of engagement with regulatory agencies appears to be independent of participants' views on the complexity of the regulatory requirements. This could imply that engagement is driven more by organizational policies, specific project needs, or regulatory mandates rather than individual perceptions of complexity.

Further Analysis and Discussion:

While the Chi-Square test indicates no significant relationship, it's still valuable to consider qualitative insights from participants about their engagement with regulatory agencies. This can provide a more nuanced understanding of the factors influencing engagement practices.

For instance, participants might have varying strategies for managing complex regulatory environments that are not captured purely by engagement frequency. These strategies could include:

- Enhanced Documentation: Preparing more detailed and comprehensive regulatory submissions to pre-empt potential queries.
- Consultation with Experts: Engaging with regulatory consultants or experts to navigate complex regulatory landscapes.
- Training and Development: Investing in continuous training for regulatory teams to better understand and manage regulatory complexities.

Incorporating these qualitative insights into the discussion provides a holistic view of how regulatory professionals handle the complexities of their work and highlights best practices that can be adopted by others in the field.

The findings suggest that the complexity of regulatory environments, while perceived differently by participants, does not necessarily impact the frequency of their engagement with regulatory agencies. This could imply that engagement practices are standardized and robust enough to handle varying complexities, which is a positive indicator for the alignment of regulatory practices with ICH guidelines (Flear, 2021).

However, the lack of a significant relationship also raises questions about whether regulatory agencies are effectively addressing the nuances of these complexities. It suggests a potential area for improvement in tailoring regulatory interactions based on the specific challenges faced by different regions or drug categories.

By understanding these dynamics, organizations can better support their regulatory teams, ensuring they have the necessary resources and strategies to effectively manage regulatory challenges and maintain compliance. This approach ultimately contributes to smoother regulatory processes and more efficient drug approvals, benefiting both the industry and public health.

In summary, the Chi-Square analysis suggests no significant association between the perceived complexity of the regulatory environment and the frequency of engagement with regulatory agencies. This highlights the potential for universal strategies in regulatory engagement, benefiting the global regulatory affairs community.

Cross-Analysis of Engagement with Regulatory Agencies Across ICH Regions

To further understand the engagement with regulatory agencies, a one-way ANOVA test was conducted to compare the frequency of engagement across different ICH regions.

ANOVA

Source	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	5.686	4	1.421	0.675	0.611
Within Groups	197.971	94	2.106		
Total	203.657	98			

Table 14: ANOVA test for frequency of engagement with regulatory agencies across ICH regions

Interpretation:

- The ANOVA test results indicate that there is no statistically significant difference in the frequency of engagement with regulatory agencies across different ICH regions ($F = 0.675$, $p = 0.611$).
- This suggests that regardless of the primary ICH region in which participants work, their frequency of engagement with regulatory agencies is similar.

Key Insights:

1. **Uniform Engagement Practices:** The lack of significant differences across ICH regions may indicate that engagement practices with regulatory agencies are fairly standardized across different regions.

2. **Global Harmonization:** This could be a positive indicator of global harmonization efforts, suggesting that regulatory professionals engage with agencies in a consistent manner irrespective of regional differences.

Conclusion:

- Both the Chi-Square and ANOVA analyses suggest that the frequency of engagement with regulatory agencies is not significantly influenced by perceived complexity or ICH region. This uniformity in engagement practices highlights the importance of consistent regulatory strategies and supports the notion of global harmonization in regulatory affairs.

4.4 Specific Approval Challenges

This section addresses the primary challenges faced by respondents in the regulatory approval process for first-in-class drugs.

4.4.1 Primary Challenges

Participants identified several primary challenges as follows:



Figure 14: Common regulatory approval challenges for first in class drugs

Interpretation of Results

- Regulatory Requirements and Guidelines: The high percentage of participants who identified regulatory requirements and guidelines as a primary challenge underscores

the complexity and variability of these requirements. Further harmonization of guidelines across regions could potentially alleviate this burden.

- Timelines and Deadlines: The significant challenge posed by timelines and deadlines suggests that regulatory agencies and pharmaceutical companies need to work together to find ways to streamline processes and allocate resources efficiently to meet these deadlines without compromising on thoroughness.
- Communication with Regulatory Agencies: The challenges in communication highlight the need for improved dialogue and transparency between regulatory agencies and pharmaceutical companies (Ofori-Asenso *et al.*, 2020). Regular updates, advisory sessions, and clear feedback mechanisms could help address this issue.
- Clinical Trial Design and Endpoints: The complexity of clinical trial design and endpoints emphasizes the need for innovative trial designs and greater regulatory support for adaptive trials and real-world evidence.
- Data Quality and Integrity: Ensuring data quality and integrity is fundamental to gaining regulatory approval (Boakai, 2024). Organizations must invest in robust data management systems and practices to ensure that their data meets regulatory standards.

4.4.2 Significance of Clinical and Evidentiary Hurdles

On a scale of 1 to 5, respondents rated the significance of clinical and evidentiary hurdles in delaying the approval of innovative treatments:



Figure 15: Significance of Clinical and Evidentiary Hurdles

Interpretation of Results

- Moderate to High Significance: The majority of participants (46% moderately significant, 39% very significant, and 6% extremely significant) indicate that clinical

and evidentiary hurdles are major challenges in the regulatory approval process. This reflects the stringent and complex nature of clinical trials and the high standards required for evidence of safety and efficacy (An *et al.*, 2020).

- Implications for Practice: Given the significant impact of these hurdles, pharmaceutical companies and regulatory agencies need to focus on strategies to address these challenges. This could include adopting more flexible trial designs, improving the integration of real-world evidence, and enhancing communication and support throughout the trial and approval processes.
- Strategic Focus: Organizations should consider investing in advanced clinical trial methodologies, such as adaptive trial designs, and leveraging technology to streamline data collection and analysis. Additionally, fostering closer collaboration with regulatory agencies can help in understanding and meeting evidentiary standards more effectively.
- Policy Recommendations: Regulatory bodies might need to provide clearer guidance and support for innovative clinical trial designs and the use of alternative evidentiary sources. This could help reduce the burden on companies while maintaining high standards for drug safety and efficacy.

4.4.3 Specific Regulatory or Clinical Challenges

Open-ended responses revealed specific challenges, such as:

- Difficulty in meeting stringent evidence requirements
- Navigating differing regional guidelines simultaneously
- Maintaining data integrity throughout the submission process

Thematic Analysis of Open-ended Responses:

- **Evidence Requirements:** The most mentioned challenge was the difficulty in meeting the stringent evidence requirements, particularly in ensuring that the evidence provided meets the standards of all regions.
- **Regional Guidelines:** Respondents frequently mentioned the complexity of navigating differing regional guidelines simultaneously. The need to comply with varying requirements in multiple regions adds to the workload and complexity.
- **Data Integrity:** Maintaining data integrity throughout the submission process was another significant challenge highlighted by the respondents.

4.5 Organizational Strategies

4.5.1 Strategies Used

Organizations use various strategies to address regulatory challenges. The following data represents the strategies employed by the respondents' organizations, along with their respective percentages:



Figure 16: Strategies employed by organizations to overcome regulatory hurdles in the approval of first in class drugs

Cross Analysis: To analyze if different types of organizations (pharmaceutical companies, biotech companies, CROs, regulatory consultancies, etc.) prioritize different strategies to overcome regulatory challenges.

ANOVA

ANOVA	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	272.723	11	24.793	0.799	0.641
Within Groups	2700.267	87	31.038		
Total	2971.990	98			

Table 15: ANOVA test to analyze if different types of organizations prioritize different strategies

Interpretation of Results:

The ANOVA results indicate that there is no statistically significant difference in the prioritization of strategies among different types of organizations (F = 0.799, p = 0.641).

This suggests that pharmaceutical companies, biotech companies, CROs, and regulatory consultancies generally prioritize similar strategies to overcome regulatory challenges.

Key Observations:

1. Uniform Strategy Use: The lack of significant difference implies that regardless of the type of organization, the strategies used to overcome regulatory challenges are quite uniform. This could be due to the standardized nature of regulatory requirements across the industry or common industry best practices being adopted widely.

2. Practical Implications: For regulatory professionals, this finding highlights the importance of established strategies that are effective across various organizational contexts. It highlights the benefit of sharing best practices and collaborative approaches to regulatory challenges.

3. Future Research: Further research could explore specific contextual factors that might influence the effectiveness of these strategies in different organizational settings. Qualitative insights could also provide a deeper understanding of why certain strategies are preferred over others.

Discussion:

The uniformity in strategy prioritization among different types of organizations might be driven by common regulatory frameworks and industry standards. Despite the varied nature of these organizations, the challenges they face in regulatory approval processes appear to necessitate similar approaches. This alignment suggests that best practices in regulatory strategy are being effectively disseminated and adopted across the industry, contributing to a more cohesive regulatory environment.

The findings suggest that different types of organizations do not significantly differ in their prioritization of strategies to overcome regulatory challenges. This uniformity may reflect the standardized regulatory requirements and shared best practices across the industry. Understanding these dynamics can help regulatory professionals and organizations adopt effective strategies that are widely recognized and proven to be successful.

4.5.2 Effectiveness of Strategies

Participants rated the effectiveness of the strategies employed by their organizations. The effectiveness ratings are as follows:



Figure 17: Perceived effectiveness of organizational strategies

ANOVA Analysis: Perceived Complexity of Regulatory Requirements vs. Perceived Effectiveness of Strategies

An ANOVA test was used to analyze if the perceived complexity of regulatory requirements influences the perceived effectiveness of strategies used by companies to overcome regulatory challenges.

ANOVA

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	11.753	4	2.938	2.414	.054
Within Groups	114.429	94	1.217		
Total	126.182	98			

Table 16: ANOVA test to analyze if the perceived complexity of regulatory requirements influences the perceived effectiveness of strategies

Interpretation of Results:

- Significance Level: The ANOVA test yields a p-value of .054, which is slightly above the conventional threshold of .05. This suggests that there is a marginally non-significant difference in the perceived effectiveness of strategies based on the perceived complexity of regulatory requirements.
- Practical Implications: While the p-value is slightly above the threshold, it is close enough to warrant further investigation. It implies that perceived complexity might influence how effective participants find certain strategies, though the evidence is not strong enough to confirm this definitively.

Key Observations:

- Variability in Effectiveness: There appears to be variability in how effective participants find the strategies based on the complexity of regulatory requirements, suggesting that the more complex the requirements, the more critical the evaluation of strategy effectiveness becomes.
- Need for Tailored Strategies: Organizations may need to tailor their strategies to better align with the perceived complexity of the regulatory environment to enhance effectiveness.

While the statistical evidence is not strong enough to confirm a significant relationship, the results suggest that there may be some influence of regulatory complexity on the perceived effectiveness of strategies. This finding highlights the importance for organizations to consider the complexity of their regulatory environment when evaluating and implementing strategies to overcome regulatory challenges.

The analysis underscores the importance of continuously assessing and adapting strategies to ensure their effectiveness in different regulatory contexts. Organizations should remain vigilant and flexible, ready to adjust their strategies in response to the changing regulatory landscape and the specific challenges they encounter.

4.5.3 Successful Initiatives

Overview

Participants highlighted several successful initiatives undertaken by organizations to overcome regulatory challenges and achieve approval for first-in-class drugs. Key initiatives include collaborative workshops with regulatory agencies, leveraging real-world evidence, and implementing adaptive trial designs.

Initiative	Example Comment
Collaborative workshops	"Workshops with regulatory agencies were very helpful."
Real-world evidence	"Using real-world evidence supported our clinical data."
Adaptive trial designs	"Adaptive trial designs helped meet regulatory expectations."

Table 17: Successful Initiatives Highlighted by Participants

Collaborative Workshops: These workshops provided a platform for direct communication between regulatory professionals and agency representatives, helping to clarify requirements and expectations early in the process, thereby reducing misunderstandings and potential rejections.

Leveraging Real-World Evidence: Integrating RWE into regulatory submissions helps bridge gaps in clinical trial data, providing a comprehensive view of a drug's impact and enhancing the robustness of the submission.

Adaptive Trial Designs: The flexibility of adaptive trial designs allows organizations to modify trial procedures based on interim results, making the trials more efficient and better aligned with regulatory expectations.

Comparison with Literature:

- These findings align with existing literature, which emphasizes the importance of collaborative approaches, RWE integration, and adaptive trial designs in regulatory submissions. Comparing these findings with literature can validate the effectiveness of these initiatives and provide broader context.

Cross Analysis: Effectiveness vs. Type of Strategy:

To further explore the effectiveness of different organizational strategies, an ANOVA test was conducted to compare the perceived effectiveness of these strategies across different types of organizations. The results are as follows:

ANOVA

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	52.423	3	17.474	0.568	0.637
Within Groups	2920.567	95	30.743		
Total	2972.990	98			

Table 18: ANOVA test to analyze if the perceived complexity of regulatory requirements influences the perceived effectiveness of strategies

Interpretation of Results

- Non-Significant Difference: The p-value (0.637) is greater than the conventional threshold of 0.05, indicating that there is no statistically significant difference in the perceived effectiveness of strategies across different types of strategies used. This suggests that the specific strategy employed (early engagement with regulatory agencies, use of accelerated approval pathways, investment in advanced clinical trial designs, collaboration with external experts, implementation of robust quality management systems) does not significantly influence how effective they are perceived to be.

- Homogeneity in Perception: The lack of significant differences implies a level of homogeneity in the perception of strategy effectiveness across various types of strategies. This could indicate that the challenges faced in regulatory affairs and the strategies employed to overcome them are broadly similar, regardless of the specific strategy used (Chisholm and Critchley, 2023) .

Practical Implications

- Standardized Approaches: Since the perceived effectiveness of strategies does not significantly vary by strategy type, there may be an opportunity to standardize certain successful initiatives across the industry. Best practices identified with one strategy could be effectively implemented with other strategies.
- Further Research: Future studies could explore whether specific contextual factors within organizations influence the effectiveness of regulatory strategies more than the strategy type itself. Factors such as organizational culture, size, and specific regulatory challenges faced could provide deeper insights.

4.6 Recommendations and Improvements

4.6.1 Recommended Improvements

Participants were asked to suggest improvements to the current regulatory approval process for first-in-class drugs. The following are the recommendations along with their respective percentages:



Figure 18: Recommended Improvements to Regulatory Processes in relation to the approval of first in class drugs

Discussion:

- **Harmonized Guidelines**: The call for more harmonized guidelines across ICH regions reflects the need for a standardized regulatory framework. Currently, variations in guidelines lead to increased complexity and duplication of efforts for pharmaceutical companies operating in multiple regions. Further harmonization could streamline the

submission process, reduce administrative burdens, and expedite patient access to innovative therapies (Beierle *et al.*, 2024).

- **Transparency and Communication**: Increased transparency and communication from regulatory agencies are crucial for building trust and clarity in the approval process (ICH, 2024). Respondents highlighted the importance of timely and clear feedback from agencies to help address issues early and avoid delays. Improved communication channels, such as regular updates and interactive sessions, could significantly enhance the efficiency of the regulatory process.
- **Faster Review Times**: Faster review times are essential to bringing innovative drugs to market more quickly (Cooper, 2021). Delays in the review process can hinder patient access to potentially life-saving treatments. Participants suggested that allocating more resources to regulatory agencies and adopting advanced review techniques could help shorten review times without compromising the thoroughness of evaluations.
- **Flexibility in Clinical Trial Requirements**: Greater flexibility in clinical trial requirements could accommodate the unique characteristics of first-in-class drugs, which often involve novel mechanisms of action and therapeutic targets (Michaeli *et al.*, 2023). Adaptive trial designs and the acceptance of real-world evidence could be part of this flexibility, allowing for more efficient and relevant data collection.
- **Enhanced Collaboration**: Enhanced collaboration between regulatory agencies and pharmaceutical companies was also emphasized. Joint workshops, advisory meetings, and collaborative research initiatives could facilitate a better understanding of regulatory expectations and innovative approaches to meet them. Such collaborations could lead to more robust and supportive regulatory environments.

4.6.2 Likelihood of Enhancing Efficiency

Respondents rated the likelihood of the recommended improvements enhancing the efficiency of the regulatory approval process:



Figure 19: Likelihood of the improvements to enhance efficiency of the regulatory approval process

Perceived Impact

The high percentage of respondents who believe that the recommended improvements are likely or very likely to enhance efficiency highlights the need for changes in the current regulatory framework. These perceptions are informed by direct experiences with the regulatory process and reflect a consensus on the potential benefits of the proposed improvements.

Implementation Challenges

While the likelihood ratings are optimistic, it is important to consider potential challenges in implementing these improvements. Regulatory agencies may face resource constraints, resistance to change, and the complexity of aligning multiple regional guidelines. Addressing these challenges will require coordinated efforts and sustained commitment from all stakeholders involved.

- **Resource Constraints**: Implementing improvements often requires additional resources, including funding, personnel, and technological infrastructure. Agencies and companies must ensure these resources are available to support the changes.
- **Resistance to Change**: Organizational inertia and resistance to new processes can hinder the implementation of improvements. It is crucial to engage stakeholders early and provide clear benefits to gain buy-in.
- **Complexity of Alignment**: Harmonizing guidelines across regions involves navigating complex legal and administrative frameworks. Effective collaboration and communication between regions are necessary to achieve alignment.

Practical Implications

The findings highlight several practical implications for enhancing the efficiency of the regulatory approval process:

- **Regulatory Harmonization**: Continued efforts to harmonize guidelines can simplify the approval process, reduce duplication of efforts, and lower costs for pharmaceutical companies.
- **Enhanced Communication**: Improving transparency and communication can lead to more predictable and efficient regulatory processes, benefiting both regulators and the pharmaceutical industry.
- **Support for Innovation**: Encouraging innovative trial designs and the use of real-world evidence can expedite the approval of first-in-class drugs, providing patients with faster access to new treatments.

Cross Analysis of Type of Organization vs. Likelihood of Enhancing Efficiency

Results

Respondents rated the likelihood of the recommended improvements enhancing the efficiency of the regulatory approval process. The analysis includes the following:

ANOVA

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	10.202	11	0.927	1.084	0.383
Within Groups	114.429	87	0.855		
Total	126.182	98			

Table 19: ANOVA Test: Likelihood of Enhancing Efficiency Across Different Types of Organizations

Key Observations from ANOVA Results:

1. **No Significant Difference:** The ANOVA results indicate that there is no statistically significant difference in the perceived likelihood of enhancing efficiency across different types of organizations. This suggests that regardless of the type of organization (pharmaceutical companies, biotech companies, CROs, regulatory consultancies, etc.), respondents share a similar outlook on the potential for these improvements to enhance efficiency.
2. **Homogeneous Perceptions:** The homogeneity in perceptions across different organizational types could imply that the challenges and potential solutions in the regulatory approval process are universally recognized and appreciated, transcending organizational boundaries.

Final Insights:

The results suggest a general consensus across different types of organizations regarding the likelihood of recommended improvements enhancing the efficiency of the regulatory approval process. This consensus highlights the widespread recognition of the need for

harmonized guidelines, increased transparency, faster review times, greater flexibility, and enhanced collaboration. However, practical implementation of these improvements requires careful consideration of the potential challenges and concerted efforts from all stakeholders involved in the regulatory landscape.

4.6.3 Additional Feedback and Suggestions

Participants provided valuable additional feedback and suggestions for improving the regulatory approval process for first-in-class drugs. The following key themes and comments were highlighted:

1. **Workshop and Presentation Attendance**

- **Suggestion:** Attend workshops and presentations on regulatory support.
- **Survey Comment:** "I would definitely recommend looking at the ICH Surveys (for adherence to ICH), Presentations from 2018 EMA/FDA Joint Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies and International Coalition of Medicines Regulatory Authorities (ICMRA) pilots currently running."

2. **Better Resources**

- **Suggestion:** Improve the resourcing of QA and regulatory teams.
- **Survey Comment:** "Better resourcing of QA and Reg teams in companies working on clinical drugs. My experience is that teams are under-resourced and overworked. This leads to mistakes that lead to delays."

3. **Limit Pharmaceutical Company Control**

- **Suggestion:** Ensure balanced collaboration between companies and regulatory agencies to avoid perceptions of undue influence.
- **Survey Comment:** "Additional collaboration between companies and agencies runs the risk of appearing to have pharma control the agencies and discredits in public opinion. More harmonization is definitely possible and would save time, but it is also pretty impressive how much we have so far. It would be amazing if we could get to a point where the US, EMA, and Canada submissions (maybe more) are made at the same time because there is nothing different expected between them. Without having that, there is generally one market that gets to go first, and the others end up waiting."

Workshop and Presentation Attendance: Participants emphasized the importance of attending workshops and presentations organized by regulatory bodies. These events provide crucial insights into current regulatory expectations and upcoming changes in the approval process. Engaging with these resources can help companies stay updated and better prepared for regulatory submissions.

Better Resources: There is a clear call for better resourcing of QA and regulatory teams. Overworked and under-resourced teams are prone to errors that can cause significant delays in the approval process. By ensuring that these teams have adequate resources, companies can improve the quality of their submissions and reduce the likelihood of delays due to mistakes.

Limit Pharmaceutical Company Control: Participants expressed concerns about the potential perception of undue influence if there is excessive collaboration between pharmaceutical companies and regulatory agencies. Maintaining a balanced and transparent relationship is crucial to preserving public trust. Additionally, there is a strong desire for further harmonization of regulatory requirements across different regions, which could streamline the approval process and reduce delays.

4.7 Comparison with Literature Review

4.7.1 Consistency with Literature

The survey findings align with the existing literature in several key areas. These consistencies reinforce the validity of the data and highlight recurring themes and challenges in the regulatory approval process for first-in-class drugs.

Regulatory Variability:

- Primary Data Insights: The survey results highlight significant variability in regulatory requirements across ICH regions. Respondents noted that this variability complicates the approval process for pharmaceutical companies operating in multiple regions.
- Literature Insights: Consistent with the literature, these findings are supported by (Botros *et al.*, 2022) , who discuss how differences in documentation, clinical trial requirements, approval timelines, and decision-making processes present significant hurdles for drug approval.

Discussion: The variability in regulatory requirements is a well-documented challenge in the literature. (Botros *et al.*, 2022) emphasizes that pharmaceutical companies often face redundant and sometimes conflicting requirements when submitting applications to multiple regulatory bodies. This complexity can lead to increased costs and extended timelines for drug approval, ultimately delaying patient access to innovative treatments. The survey responses underscore this issue, with participants expressing frustration over the need to navigate different regulatory landscapes simultaneously.

Challenges in Clinical Trials:

- Primary Data Insights: Participants in the survey highlighted clinical trial design and endpoints as primary challenges, with 28% identifying this as a significant issue.
- Literature Insights: These findings are corroborated by (Selker *et al.*, 2019), who discuss the difficulties in designing clinical trials that meet the diverse regulatory expectations. The variation in evidentiary standards and trial design requirements across regions can significantly delay drug approval.

Discussion: The design of clinical trials is a critical component of the drug approval process, and the survey findings echo the challenges discussed in the literature. (Selker *et al.*, 2019) note that the inconsistency in trial design requirements, such as differences in accepted endpoints and patient population criteria, can create significant barriers for sponsors. These discrepancies necessitate the creation of multiple trial protocols to satisfy regional regulators, further complicating the development process. The primary data from this survey highlights the real-world impact of these challenges, with

respondents emphasizing the need for harmonized trial design standards to streamline the approval process.

Theme	Primary Data Insights	Literature Insights
Regulatory Variability	Significant differences in requirements across ICH regions	Variability complicates approval process (Botros *et al.*, 2022)
Challenges in Clinical Trials	Difficulties in meeting diverse regulatory expectations for trials	Varying standards delay approvals (Selker *et al.*, 2019)

Table 20: Consistencies Between Primary Data and Literature

4.7.2 Implications of Consistency

The alignment between the survey findings and existing literature has several important implications:

1. Validation of Findings: The consistency between primary and secondary data validates the survey results, lending credibility to the findings. This alignment suggests that the challenges and themes identified in the survey are reflective of broader trends in the regulatory landscape.

2. Reinforcement of Themes: The recurring themes in both the survey and literature highlight persistent issues in the regulatory approval process for first-in-class drugs. These include regulatory variability and challenges in clinical trial design, both of which are significant barriers to efficient drug development and approval.

3. Policy and Practice Implications: The findings underscore the need for policy reforms aimed at harmonizing regulatory requirements and supporting innovative trial designs. By addressing these issues, regulatory agencies can facilitate a more streamlined and efficient approval process, ultimately benefiting both pharmaceutical companies and patients.

4.7.3 Recommendations for Future Research

While the survey and literature provide valuable insights, further research is needed to explore the following areas:

1. Harmonization Efforts: Investigate the impact of ongoing harmonization efforts by regulatory bodies, such as the ICH, on the approval process for first-in-class drugs. Assess the effectiveness of these initiatives in reducing variability and improving efficiency.

2. Innovative Trial Designs: Examine the adoption and impact of innovative trial designs, such as adaptive trials and the use of real-world evidence, on the regulatory approval process. Identify best practices and potential barriers to implementation.

3. Stakeholder Perspectives: Conduct qualitative research to gather in-depth perspectives from various stakeholders, including regulatory professionals,

pharmaceutical companies, and patient advocacy groups. This will provide a comprehensive understanding of the challenges and potential solutions in the regulatory landscape.

4. Global Regulatory Comparisons: Expand research to compare the regulatory frameworks and approval processes in non-ICH regions with those of ICH regions. This can provide insights into how global harmonization might be achieved and highlight alternative approaches that could be beneficial in ICH regions.

5. Longitudinal Studies on Approval Timelines: Investigate changes in drug approval timelines over time, particularly in response to regulatory innovations or reforms. A longitudinal study could reveal whether recent efforts to expedite approvals have had a lasting impact on efficiency.
6. Impact of Technological Advancements: Explore how emerging technologies, such as artificial intelligence (AI) and machine learning, can be integrated into the regulatory process. Research could focus on how these technologies can improve the speed and accuracy of drug evaluations and what challenges need to be addressed to implement them effectively.

7. Patient-Centric Approaches: Future research should investigate how patient input, such as patient-reported outcomes or preferences, can be systematically incorporated into the regulatory approval process. This could also include examining the role of patient advocacy groups in shaping regulatory policies.

8. Economic Implications of Regulatory Strategies: Conduct economic analyses to assess the cost-effectiveness of different regulatory strategies, such as accelerated approval pathways or the use of real-world evidence. Understanding the economic impact can help in designing strategies that balance speed with cost efficiency.

9. Training and Education for Regulatory Professionals: Explore the need for continuous professional development in the regulatory field. Research could identify gaps in current training programs and suggest ways to better prepare regulatory professionals for the evolving landscape, especially regarding new technologies and methodologies.

10. Public Perception and Trust in Regulatory Decisions: Investigate how public trust in the regulatory process is influenced by factors such as transparency, communication, and the handling of accelerated approvals. This research could help in developing strategies to maintain and enhance public confidence in regulatory bodies.

By addressing these research areas, future studies can contribute to a more nuanced understanding of the regulatory approval process and inform strategies to enhance the efficiency and effectiveness of drug development and approval.

4.8 Implications for Practice and Policy

The findings from this study have several practical implications that can inform both industry practices and regulatory policies. By understanding the primary challenges and effective strategies in the regulatory approval process, stakeholders can develop more efficient and supportive frameworks for first-in-class drug approvals (Franco *et al.*, 2023).

4.8.1 Regulatory Harmonization

One of the most significant implications is the need for continued efforts toward harmonizing regulatory requirements across ICH regions. The survey results and literature consistently highlight the variability in regulatory standards as a major challenge for pharmaceutical companies. This variability can lead to increased costs, longer approval times, and potential delays in patient access to innovative therapies.

- **Harmonized Guidelines:** Developing more harmonized guidelines across ICH regions can reduce the administrative burden on pharmaceutical companies. It can also streamline the approval process, making it more predictable and efficient (CDER, 2023). This is especially important for first-in-class drugs, which often face more stringent scrutiny and higher evidentiary requirements.

Implication	Expected Outcome
Reduced Administrative Burden	Lower costs and resource requirements for companies
Streamlined Approval Process	Faster approval times and earlier patient access to therapies
Predictability and Efficiency	More consistent and transparent regulatory expectations

Table 21: Implications of Regulatory Harmonization

4.8.2 Enhanced Communication

Improving transparency and communication between regulatory agencies and pharmaceutical companies can address many of the challenges identified in this study. Effective communication can help clarify regulatory expectations, reduce misunderstandings, and facilitate a more collaborative approach to drug development and approval (Ofori-Asenso *et al.*, 2020).

- Regular Interaction: Encouraging regular interaction through meetings, workshops, and advisory sessions can help both parties stay aligned. This can lead to more informed decision-making and quicker resolution of issues that arise during the approval process (Hogervorst *et al.*, 2023).

Benefit	Description
Clarified Expectations	Clearer guidelines and requirements for companies
Reduced Misunderstandings	Fewer delays and rejections due to misinterpretation of regulations
Collaborative Approach	Enhanced cooperation and mutual understanding between stakeholders

Table 22: Benefits of Enhanced Communication

4.8.3 Support for Innovation

Providing greater regulatory support for innovative clinical trial designs and the use of real-world evidence can significantly improve the approval process for first-in-class drugs. Innovation in trial designs, such as adaptive trials, can provide more robust data while reducing the time and cost associated with traditional clinical trials (Baumfeld Andre *et al.*, 2020).

- Regulatory Flexibility: Agencies should consider more flexible approaches to trial design and evidence requirements. This can include accepting surrogate endpoints or interim results to expedite the approval process while ensuring patient safety and efficacy**.**

Innovative Practice	**Regulatory Support Needed**
Adaptive Trial Designs	Acceptance of interim results and flexible protocols
Real-World Evidence	Integration of real-world data into approval criteria
Surrogate Endpoints	Consideration of surrogate markers for earlier approvals

Table 23: Support for Innovative Practices

4.8.4 Policy Recommendations

- Based on the findings, several policy recommendations can be made to improve the regulatory approval process:
- Develop Harmonized Guidelines: Regulators in ICH regions should work towards developing and implementing harmonized guidelines to minimize variability.
- Enhance Transparency and Communication: Regular interaction and clear communication channels between regulatory bodies and pharmaceutical companies should be established.
- Support Innovative Designs: Regulatory frameworks should be adapted to support innovative clinical trial designs and the use of real-world evidence.
- Implement Training Programs: Continuous professional development programs for regulatory professionals to stay updated with evolving regulations and practices.

Recommendation	**Description**
Harmonized Guidelines	Develop consistent regulations across ICH regions
Enhanced Communication	Establish regular interaction and clear communication channels
Support for Innovation	Adapt frameworks to support innovative designs and real-world evidence
Training Programs	Implement continuous professional development programs

Table 24: Policy Recommendations

The variability in responses regarding the complexity and effectiveness of regulatory strategies suggests that individual and organizational factors significantly influence perceptions. Further research could explore these factors in more detail.

4.9 Conclusion

This chapter has presented and analyzed the findings from the survey, comparing them with the literature review to draw meaningful insights. The results highlight significant challenges in the regulatory approval process for first-in-class drugs, including variability in requirements, scientific uncertainties, and market access barriers. Organizational strategies to address these challenges include early engagement with regulatory agencies, the use of accelerated approval pathways, and investment in advanced clinical trial designs.

4.9.1 Summary of Key Findings

1. **Participant Demographics and Background:**

- The majority of respondents have extensive experience in regulatory affairs, with significant representation from the EU and US regions.
- The diverse organizational backgrounds of participants (pharmaceutical companies, biotech firms, CROs, and regulatory consultancies) provide a comprehensive view of the industry.

2. **Global Regulatory Landscape:**

- There is a high level of familiarity with EMA and FDA frameworks among respondents.
- The complexity of regulatory requirements varies, with a significant portion finding them complex or very complex.
- Differences in regulatory requirements across ICH regions pose challenges, particularly in documentation, clinical trial expectations, and approval timelines.

3. **Specific Approval Challenges:**

- Major challenges include stringent regulatory requirements, clinical trial design, data quality, communication with regulatory agencies, and timelines.
- Clinical and evidentiary hurdles significantly impact the approval process, often causing delays.

4. **Organizational Strategies:**

- Effective strategies include early engagement with regulatory agencies, the use of accelerated approval pathways, investment in advanced clinical trial designs, and collaboration with external experts.
- The effectiveness of these strategies is generally positive, though some variability exists based on regional and organizational differences.

5. **Recommendations and Improvements:**

- Suggested improvements focus on harmonizing guidelines, increasing transparency, expediting review times, and enhancing collaboration.
- Respondents believe these improvements are likely to enhance the efficiency of the regulatory approval process.

Implications for Practice and Policy

The findings underscore the necessity for regulatory harmonization, enhanced communication, and support for innovation. By addressing these areas, regulatory agencies and pharmaceutical companies can work together more effectively to streamline the approval process for first-in-class drugs.

- **Regulatory Harmonization:** Efforts should be intensified to develop harmonized guidelines across ICH regions. This can alleviate the administrative burden on companies and expedite patient access to new therapies.
- **Enhanced Communication:** Regular, transparent communication between regulatory bodies and companies can clarify expectations, reduce misunderstandings, and foster a collaborative environment.
- **Support for Innovation:** Regulatory frameworks should adapt to support innovative trial designs and the integration of real-world evidence, facilitating the approval of innovative treatments.

Critique:

While the study provides valuable insights, it also highlights areas for further research and potential critique:

- **Variability in Responses:** The diversity in responses, particularly regarding the complexity and effectiveness of regulatory strategies, suggests that individual and organizational factors play a significant role. Future research could delve deeper into these factors.
- **Effectiveness by Region:** A cross-analysis of the effectiveness of organizational strategies by region could reveal if certain strategies are perceived as more effective in specific contexts. This would help tailor approaches to regional regulatory environments.

4.9.2 Limitations of the Study

It is essential to acknowledge the limitations of this study to provide context for the findings and recommendations:

- **Sample Size and Diversity:** While the sample size is adequate, a larger and more diverse sample could provide more generalizable results.
- **Self-Reported Data:** The reliance on self-reported data from survey respondents may introduce bias, as participants might provide socially desirable responses.

- **Regional Focus:** The study primarily focuses on the EU, US, and Japan, potentially overlooking regulatory challenges and strategies in other significant markets for example, Canada.

Future Research Directions

To build on the findings of this study, future research could explore the following areas:

- **In-Depth Regional Analysis:** Conducting region-specific studies to understand better the unique regulatory challenges and strategies in different global markets.
- **Longitudinal Studies:** Implementing longitudinal research to track changes in regulatory practices and their impact over time.
- **Qualitative Insights:** Incorporating qualitative methods, such as interviews and case studies, to gain deeper insights into the experiences and perspectives of regulatory professionals.

By pursuing these research directions, future studies can continue to enhance our understanding of the regulatory approval process for first-in-class drugs and contribute to the development of more efficient and effective regulatory frameworks.

Chapter Five: Conclusion

5.1 Introduction

- This chapter provides a comprehensive overview of the key findings, their implications, and how they align or contrast with existing literature. It outlines practical and academic recommendations, highlights the limitations of the study, and suggests areas for further research. The chapter concludes with a personal reflection on the learning journey undertaken during the dissertation process. The purpose of this chapter is to synthesize the research findings, draw meaningful conclusions, and propose actionable steps to enhance the regulatory approval process for first-in-class drugs in ICH regions (EU, USA, Japan).

5.2 Summary of Main Findings and Implications

Main Findings

Regulatory Challenges:

- Stringent Requirements: Primary challenges include stringent regulatory requirements, complex clinical trial designs, data quality and integrity issues, communication barriers with regulatory agencies, and tight timelines. These challenges are compounded by the high stakes involved in developing first-in-class drugs, which often involve novel mechanisms of action and require extensive evidence to demonstrate their safety and efficacy.

Organizational Strategies:

- Effective Strategies: Successful strategies to overcome these challenges involve early engagement with regulatory agencies, leveraging accelerated approval pathways, investing in advanced clinical trial designs, collaborating with external experts, and implementing robust quality management systems. These strategies are crucial for navigating the complex regulatory landscape and ensuring that innovative therapies reach patients as quickly and safely as possible.

Global Regulatory Landscape:

- Variability in Requirements: Significant variability exists in regulatory requirements across ICH regions, with notable differences in documentation, approval timelines, and data quality expectations. This variability can create substantial hurdles for pharmaceutical companies operating internationally, necessitating region-specific strategies and extensive regulatory expertise.

Effectiveness of Strategies:

- Regional Specificity Needed: While most strategies are perceived as effective, there is a need for region-specific approaches to address unique regulatory landscapes. The effectiveness of these strategies can vary based on factors such as the specific

regulatory environment, the type of drug being developed, and the resources available to the organization.

Recommendations for Improvement:

- Key Recommendations: Key recommendations include harmonizing guidelines across ICH regions, enhancing transparency and communication, speeding up review times, increasing flexibility in clinical trial requirements, and fostering collaboration between regulatory agencies and pharmaceutical companies. Implementing these recommendations can help streamline the approval process and improve access to innovative therapies.

Implications

For Regulatory Practice:

- The findings underscore the need for more harmonized regulatory practices to reduce the burden on pharmaceutical companies and expedite patient access to innovative therapies. Further harmonization can lead to more predictable and efficient regulatory processes, benefiting both the industry and public health, also identified by (Church and Naugler, 2019).

For Pharmaceutical Organizations:

- The identified strategies and recommendations provide a roadmap for organizations to navigate regulatory challenges more effectively, potentially leading to faster drug approvals and improved patient outcomes. Companies can adopt best practices such as early engagement with regulators and the use of adaptive trial designs to enhance their regulatory submissions also highlighted by (Baumfeld Andre *et al.*, 2020)

For Policymakers:

- The study highlights the critical areas where policy interventions can streamline regulatory processes and enhance the efficiency of drug approval mechanisms. Policymakers can play a key role in promoting regulatory harmonization, fostering international collaboration, and supporting innovative regulatory approaches, which was noted also in the paper by (Guzman *et al.*, 2020).

Detailed Implications for Key Stakeholders

For Regulatory Agencies:

- Harmonization Efforts: Regulatory agencies can work towards developing and implementing harmonized guidelines across ICH regions to minimize variability and reduce the administrative burden on pharmaceutical companies as previously indicated by (Niazi *et al.*, 2022). This can involve aligning documentation requirements, standardizing clinical trial expectations, and synchronizing approval timelines.

- Enhanced Communication Channels: Agencies should establish regular communication channels with pharmaceutical companies, including interactive

workshops, advisory sessions, and feedback mechanisms. These channels can help clarify regulatory expectations, address issues proactively, and build trust between stakeholders.

- Adoption of Innovative Practices: Regulatory agencies can support the use of innovative clinical trial designs, such as adaptive trials, and the integration of real-world evidence into the approval process. These practices can help expedite the review process while ensuring the robustness of the evidence base.

For Pharmaceutical Companies:

- Early Engagement with Regulators: Companies should prioritize early and proactive engagement with regulatory agencies to understand their expectations and requirements. This can help identify potential issues early in the development process and facilitate smoother regulatory submissions.

- Investment in Advanced Trial Designs: Organizations should invest in advanced clinical trial designs, such as adaptive trials and the use of surrogate endpoints, to generate robust evidence efficiently. This can enhance the likelihood of regulatory approval and reduce the time and cost associated with traditional trial designs.

- Collaboration with External Experts: Collaborating with external experts, including regulatory consultants and academic researchers, can provide valuable insights and support in navigating complex regulatory landscapes. These collaborations can enhance the quality of regulatory submissions and increase the chances of successful approval.

For Policymakers:

- Support for Regulatory Harmonization: Policymakers should advocate for, and support initiatives aimed at harmonizing regulatory guidelines across ICH regions. This can involve participating in international forums, promoting bilateral and multilateral agreements, and facilitating cross-regional collaboration.

- Promotion of Transparency and Efficiency: Policymakers can encourage regulatory agencies to adopt transparent and efficient review processes, including the use of modern review technologies and increased staffing. This can help reduce review times and improve the overall efficiency of the approval process.

- Encouragement of Patient-Centric Approaches: Policymakers should support the incorporation of patient feedback and real-world evidence into regulatory decision-making. This can help ensure that regulatory processes are responsive to patient needs and that approved therapies are both safe and effective in real-world settings.

5.3 Summary of Differences with Literature

This study's findings reveal both consistencies and divergences when compared with existing literature on regulatory challenges and strategies for first-in-class drug approvals across ICH regions.

Regulatory Variability:

The study's confirmation of significant variability in regulatory requirements across ICH regions aligns with the broader body of literature. Studies such as those by (Botros *et al.*, 2022) and (Asano *et al.*, 2021) emphasize the challenges posed by differing documentation standards, clinical trial requirements, and approval timelines among the EMA, FDA, and PMDA. These regulatory differences complicate the global drug approval process, as noted in both the literature and the survey data, which highlighted that respondents from different regions face distinct challenges due to these variations.

Early Engagement and Accelerated Pathways:

The importance of early engagement with regulatory agencies and the use of accelerated approval pathways, which was a key finding in this study, resonates with findings in the literature. The work by (Eichler *et al.*, 2019) and (Teixeira *et al.*, 2020) supports the view that early and frequent interactions with regulators can smooth the approval process and increase the likelihood of successful submissions. However, while the findings are consistent with these studies, they also reveal that the perceived effectiveness of these strategies varies depending on the regional context, suggesting that a one-size-fits-all approach may not be universally applicable.

Differences:

Perceived Complexity:

A notable difference between this study's findings and the existing literature is in the perceived complexity of regulatory processes. The literature, such as studies by (Vallano *et al.*, 2023) and (Omae *et al.*, 2022), often reports uniformly high complexity in regulatory requirements across regions. However, the survey indicated variability in how participants perceived this complexity, with some finding it only moderately challenging. This divergence could stem from individual experiences, varying levels of organizational support, or differences in familiarity with the regulatory environment. This insight suggests that while the regulatory environment is complex, its perceived difficulty might be mitigated by factors such as experience or institutional resources.

Effectiveness of Strategies:

Literature on the efficacy of accelerated approval pathways, such as studies by (Wang, 2023) and (Horgan *et al.*, 2020), generally highlights these as highly effective tools for speeding up the drug approval process. However, the study reveals mixed perceptions regarding their effectiveness, with some respondents suggesting that the success of these strategies depends heavily on the specific regional regulatory environment and the organizational context. This nuanced finding suggests that while these pathways are valuable, their implementation and outcomes can vary significantly, which is less emphasized in the existing literature.

Additional Insights from Primary Data:

Variability in Regulatory Experiences:

The primary data shed light on the significant variability in regulatory experiences among respondents, a point that is somewhat underexplored in the existing literature. While the literature acknowledges regional differences in regulatory frameworks, this study provides a more granular view of how these differences manifest in practice. For example, some

participants reported straightforward interactions with regulatory agencies, while others faced substantial challenges. This variability underscores the need for context-specific strategies and highlights the importance of flexibility in regulatory approaches, which is a critical addition to the existing body of knowledge.

Regional Differences in Priorities:

The study also revealed regional differences in regulatory priorities, which align with but also expand upon the literature. For instance, the emphasis by EU respondents on added therapeutic value and comprehensive clinical data contrasts with the USA focus on flexible trial designs and the acceptance of surrogate endpoints, as highlighted by (Kumari *et al.*, 2024) and (Teixeira *et al.*, 2020). These findings suggest that regional regulatory agencies not only operate under different frameworks but also prioritize different aspects of drug development, reflecting broader policy goals and healthcare priorities.

By integrating these findings with the literature, this study contributes a more nuanced understanding of how regulatory practices and perceptions vary across regions, offering valuable insights for tailoring regulatory strategies to specific contexts.

5.4 Recommendations

5.4.1 Practical Recommendations

Harmonization of Guidelines: There is a clear need to develop more consistent regulatory guidelines across ICH regions. Harmonization would greatly simplify the approval process by reducing the administrative burden on pharmaceutical companies. This consistency would also lead to a more predictable and efficient regulatory process. A key element of this harmonization involves aligning documentation requirements to minimize redundancy and streamline approvals. Moreover, synchronizing approval timelines across regions is vital to ensure that pharmaceutical companies receive timely and consistent feedback from all relevant agencies, facilitating smoother and faster approval processes.

Enhanced Communication: Improving communication channels between pharmaceutical companies and regulatory agencies is crucial. Clear and regular communication can clarify requirements and expectations early in the process, thereby reducing the likelihood of misunderstandings, delays, or rejections. Organizing regular meetings and workshops would provide a platform for regulatory agencies and pharmaceutical companies to discuss specific requirements, expectations, and best practices. Additionally, implementing formal feedback mechanisms would enable companies to receive detailed and timely feedback on their submissions, allowing them to address any issues or deficiencies promptly.

Faster Review Processes: To bring innovative therapies to market more quickly, it is essential to implement measures that accelerate the review process. This could involve increasing staffing levels at regulatory agencies, adopting advanced review technologies, and streamlining procedural frameworks. Ensuring that regulatory agencies have sufficient resources to manage the volume of submissions will help to conduct timely and thorough reviews. Furthermore, embracing modern review technologies, such as artificial

intelligence and big data analytics, can significantly enhance the efficiency and accuracy of regulatory evaluations.

Flexible Clinical Trial Requirements: Adopting more flexible and adaptive clinical trial designs is important to accommodate innovative treatment approaches. Regulatory agencies should support the use of surrogate endpoints and real-world evidence in the approval process to expedite the availability of new treatments. Encouraging adaptive trial designs, which allow for modifications based on interim results, would facilitate more efficient and responsive data collection. Integrating real-world evidence into regulatory submissions provides a more comprehensive understanding of a drug's safety and efficacy in real-world settings, making the approval process more reflective of actual patient experiences.

5.4.2 Academic Recommendations

Further Research on Regional Strategies: Conducting studies that focus on identifying and validating region-specific strategies for regulatory approval is crucial for understanding regional nuances and enhancing the effectiveness of regulatory processes. Key research questions to explore include:

1. What are the most effective regulatory strategies in different ICH regions?
2. How do regional healthcare priorities influence regulatory practices and expectations?

Impact of Regulatory Changes: Longitudinal studies that investigate the long-term effects of recent regulatory changes on drug approval times and patient outcomes are necessary to gain insights into the evolving regulatory landscape. Relevant research questions include:

1. How have recent changes in regulatory policies impacted the speed and quality of drug approvals?
2. What are the long-term outcomes for patients receiving therapies approved under new regulatory frameworks?

Comparative Studies: Conducting comparative studies across different regions and industries can uncover best practices in regulatory processes that could be adopted more broadly. Research in this area might explore:

1. What regulatory practices from other industries could be applied to pharmaceutical regulation?
2. How do different countries approach the regulation of innovative therapies, and what lessons can be learned?

5.5 Limitations and Contributions

Limitations

The study has several limitations that should be considered when interpreting the findings:

Sample Size**:** The study's sample size was relatively small, which could limit the generalizability of the findings. A larger sample size would provide more robust data and more representative insights, helping to validate the conclusions drawn from this research.

Regional Focus**:** This research primarily focused on ICH regions, potentially overlooking the regulatory challenges faced in non-ICH countries, which can have different regulatory landscapes. Future research should include a broader geographic scope to provide a more comprehensive understanding of global regulatory practices.

Survey Design**:** The reliance on self-reported data through surveys could introduce biases, such as social desirability bias, where respondents might provide answers, they believe are expected or favourable rather than their true experiences. This can affect the accuracy and reliability of the findings.

Contributions

Despite these limitations, the study makes significant contributions to the field:

Empirical Data: The study provides empirical data on the regulatory challenges and strategies in the pharmaceutical industry, contributing to a better understanding of the current landscape. This data can inform future research and policy decisions, offering a foundation for further exploration into regulatory practices.

Practical Insights: The research offers actionable insights and recommendations for pharmaceutical organizations and regulatory bodies to improve their practices. These insights can help companies navigate regulatory challenges more effectively, enhancing the efficiency of the approval process and facilitating the timely introduction of innovative therapies.

Theoretical Contribution: The study contributes to the existing body of knowledge by highlighting the need for harmonized and flexible regulatory practices. It supports the development of more effective regulatory frameworks by illustrating how regulatory variability impacts the approval process and identifying strategies that can mitigate these challenges. This theoretical contribution can guide future research and policy-making efforts aimed at improving regulatory practices globally.

5.6 Suggestions for Further Research

Broader Geographic Scope: Future research should expand to include regulatory challenges and strategies in non-ICH regions. This approach can provide a more global perspective on regulatory practices and identify unique challenges and opportunities in different markets. Specific research questions to explore include:

- What regulatory challenges are faced by pharmaceutical companies in non-ICH countries?
- How can regulatory practices in non-ICH regions be harmonized with ICH guidelines?

Longitudinal Studies: Conducting longitudinal studies to assess the impact of regulatory changes over time can offer valuable insights. These studies can track the evolution of

regulatory practices and their effects on drug approval times and patient outcomes. Key research questions in this area include:

- How do regulatory practices evolve over time in response to new challenges and innovations?
- What are the long-term impacts of regulatory changes on drug development and patient outcomes?

Qualitative Research: Utilizing qualitative methods, such as interviews and case studies, can provide deeper insights into the specific challenges and strategies employed by pharmaceutical organizations. This qualitative approach can complement quantitative data and offer a richer understanding of the issues. Important research questions might include:

- What are the lived experiences of regulatory professionals in navigating complex regulatory landscapes?
- How do organizations develop and implement effective regulatory strategies?

Impact of Technological Advances: Exploring how emerging technologies, such as artificial intelligence and big data analytics, can streamline regulatory processes and improve drug approval times is crucial. These technologies have the potential to revolutionize regulatory practices. Relevant research questions include:

- How can AI and big data analytics be integrated into the regulatory review process?
- What are the benefits and challenges of using advanced technologies in regulatory practices?

Patient-Centric Approaches: Investigating the role of patient feedback and real-world evidence in shaping regulatory guidelines and approval processes can enhance the relevance and impact of regulatory decisions. Understanding patient perspectives is critical. Key research questions in this area include:

- How can patient feedback be systematically integrated into regulatory decision-making?
- What is the impact of real-world evidence on the approval and post-marketing surveillance of new therapies?

5.7 Conclusion

In conclusion, this study has provided valuable insights into the regulatory challenges faced by pharmaceutical organizations in ICH regions and the strategies they employ to overcome these challenges. The findings highlight the need for harmonized regulatory practices, enhanced communication, and more flexible clinical trial requirements. While the study has its limitations, it contributes significantly to the field by offering practical recommendations and identifying areas for further research. Reflecting on this journey, it is evident that addressing the complexities of regulatory processes is crucial for ensuring timely access to innovative therapies and improving patient outcomes.

Personal Reflection

This dissertation has been a significant learning experience, providing an opportunity to delve deep into the complexities of regulatory science and its impact on the pharmaceutical industry. The research process has involved extensive literature review, survey design and implementation, data analysis, and critical reflection on the findings. Throughout this journey, I have gained a deeper understanding of the regulatory landscape, the challenges faced by pharmaceutical organizations, and the strategies that can enhance the efficiency of the approval process.

The insights gained from this study will not only contribute to academic knowledge but also have practical implications for improving regulatory practices and accelerating the approval of life-saving therapies. By addressing the identified challenges and implementing the recommended strategies, stakeholders in the pharmaceutical industry can work towards more efficient and effective regulatory processes, ultimately benefiting patients and advancing public health.

The journey of conducting this dissertation has been both challenging and rewarding. It has required a balance of analytical thinking, attention to detail, and a commitment to rigor and integrity in research. The experience has enriched my understanding of regulatory science and equipped me with valuable skills that will be beneficial in my future career endeavors.

References and Bibliography

Aguinis, H. *et al.* (2020) 'Actionable Recommendations for Narrowing the Science-Practice Gap in Open Science'. *Organizational Behavior and Human Decision Processes*, 158, pp. 27–35. DOI: 10.1016/j.obhdp.2020.02.007.

Åkerblad, L., Seppänen-Järvelä, R. and Haapakoski, K. (2021) 'Integrative Strategies in Mixed Methods Research'. *Journal of Mixed Methods Research*, 15(2), pp. 152–170. DOI: 10.1177/1558689820957125.

An, M.-W. *et al.* (2020) 'Principles of Good Clinical Trial Design'. *Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer*, 15(8), pp. 1277–1280. DOI: 10.1016/j.jtho.2020.05.005.

Andrade, C. (2019) 'The P Value and Statistical Significance: Misunderstandings, Explanations, Challenges, and Alternatives'. *Indian Journal of Psychological Medicine*, 41(3), pp. 210–215. DOI: 10.4103/IJPSYM.IJPSYM_193_19.

Andreoletti, M. and Blasimme, A. (2023) 'Accelerated Drug Approval: Meeting the Ethical Yardstick'. *Bioethics*, 37(7), pp. 647–655. DOI: 10.1111/bioe.13191.

Asano, K. *et al.* (2021) 'Points to Consider for Implementation of the ICH E17 Guideline: Learning from Past Multiregional Clinical Trials in Japan'. *Clinical Pharmacology & Therapeutics*, 109(6), pp. 1555–1563. DOI: 10.1002/cpt.2121.

Bahans, C. *et al.* (2021) 'Ethical Considerations of the Dynamics of Clinical Trials in an Epidemic Context: Studies on COVID-19'. *Ethics, Medicine and Public Health*, 16, p. 100621. DOI: 10.1016/j.jemep.2020.100621.

Bakker, E. *et al.* (2023) 'Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making'. *Clinical Pharmacology & Therapeutics*, 113(1), pp. 135–151. DOI: 10.1002/cpt.2766.

Baran-Kooiker, A., Czech, M. and Kooiker, C. (2019) 'Overview of Regulatory Initiatives in the European Union to Stimulate Research and Accelerate Access to Orphan Drugs and Other High Medical Need Products'. *Acta Poloniae Pharmaceutica*, 76(1). DOI: 10.32383/appdr/93138.

Barrios, C. *et al.* (2023) 'Barriers in Access to Oncology Drugs — a Global Crisis'. *Nature Reviews Clinical Oncology*, 20(1), pp. 7–15. DOI: 10.1038/s41571-022-00700-7.

Baumfeld Andre, E. *et al.* (2020) 'Trial Designs Using Real-world Data: The Changing Landscape of the Regulatory Approval Process'. *Pharmacoepidemiology and Drug Safety*, 29(10), pp. 1201–1212. DOI: 10.1002/pds.4932.

Beierle, J. *et al.* (2024) *Toward a Single Global Control Strategy: Industry Study | Pharmaceutical Engineering*. Available at: https://ispe.org/pharmaceutical-engineering/january-february-2022/toward-single-global-control-strategy-industry (Accessed: 4 August 2024).

Boakai, J. (2024) 'Data Integrity Considerations in Pharma and Life Sciences'. *European Pharmaceutical Review*. Available at:

https://www.europeanpharmaceuticalreview.com/article/219686/data-integrity-considerations-in-pharma-and-life-sciences/ (Accessed: 4 August 2024).

Bode, G. (2020) 'Regulatory Guidance: ICH, EMA, FDA'. In Hock, F.J. and Gralinski, M.R. (eds.) *Drug Discovery and Evaluation: Methods in Clinical Pharmacology*. Cham: Springer International Publishing, pp. 1085–1138. DOI: 10.1007/978-3-319-68864-0_58.

Botros, S., Botros, M. and Botros, N. (2022) 'A Comparison of the Drug Approval Process in the United States and Canada'. *International Journal of Drug Regulatory Affairs*, 10, pp. 1–8. DOI: 10.22270/ijdra.v10i2.514.

Bouwman, M.L., Sousa, J.J.S. and Pina, M.E.T. (2020) 'Regulatory Issues for Orphan Medicines: A Review'. *Health Policy and Technology*, 9(1), pp. 115–121. DOI: 10.1016/j.hlpt.2019.11.008.

Braun, V. and Clarke, V. (2022) 'Conceptual and Design Thinking for Thematic Analysis.' *Qualitative Psychology*, 9(1), pp. 3–26.

Burr, J.S. *et al.* (2019) 'Implementing a Central IRB Model in a Multicenter Research Network'. *Ethics & Human Research*, 41(3), pp. 23–28. DOI: 10.1002/eahr.500016.

Cavaleri, M. *et al.* (2021) 'Shaping EU Medicines Regulation in the Post COVID-19 Era'. *The Lancet Regional Health - Europe*, 9, p. 100192. DOI: 10.1016/j.lanepe.2021.100192.

Cave, A., Kurz, X. and Arlett, P. (2019) 'Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe'. *Clinical Pharmacology and Therapeutics*, 106(1), pp. 36–39. DOI: 10.1002/cpt.1426.

CBO. (2021) *Research and Development in the Pharmaceutical Industry | Congressional Budget Office*. Available at: https://www.cbo.gov/publication/57126 (Accessed: 15 August 2024).

CDER. (2024) *Advancing Health Through Innovation: New Drug Therapy Approvals 2023*.

CDER. (2023) 'FDA Works Through ICH to Support Global Drug Development: Creating Harmonized Technical Standards Through Guidelines'. *FDA*. Available at: https://www.fda.gov/drugs/cder-conversations/fda-works-through-ich-support-global-drug-development-creating-harmonized-technical-standards (Accessed: 3 August 2024).

CDER. (2021) 'Surrogate Endpoint Resources for Drug and Biologic Development'. *FDA*. Available at: https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development (Accessed: 15 August 2024).

Chisholm, O. and Critchley, H. (2023) 'Future Directions in Regulatory Affairs'. *Frontiers in Medicine*, 9, p. 1082384. DOI: 10.3389/fmed.2022.1082384.

Chiu, K. *et al.* (2022) 'New Science, Drug Regulation, and Emergent Public Health Issues: The Work of FDA's Division of Applied Regulatory Science'. *Frontiers in Medicine*, 9, p. 1109541. DOI: 10.3389/fmed.2022.1109541.

Church, D.L. and Naugler, C. (2019) 'Benefits and Risks of Standardization, Harmonization and Conformity to Opinion in Clinical Laboratories'. *Critical Reviews in Clinical Laboratory Sciences*, 56(5), pp. 287–306. DOI: 10.1080/10408363.2019.1615408.

Ciani, O. *et al.* (2023) 'A Framework for the Definition and Interpretation of the Use of Surrogate Endpoints in Interventional Trials'. *eClinicalMedicine*, 65, p. 102283. DOI: 10.1016/j.eclinm.2023.102283.

CIRS. (2022) *New Drug Approvals in Six Major Authorities 2012-2021: Focus on Facilitated Regulatory Pathways and Internationalisation*.

Cooper, R.G. (2021) 'Accelerating Innovation: Some Lessons from the Pandemic'. *The Journal of Product Innovation Management*, 38(2), pp. 221–232. DOI: 10.1111/jpim.12565.

Cortes, J. *et al.* (2020) 'Enhancing Global Access to Cancer Medicines'. *CA: A Cancer Journal for Clinicians*, 70(2), pp. 105–124. DOI: 10.3322/caac.21597.

da Costa Gonçalves, F., Demirci, E. and Zwiers, A. (2022) 'A Detailed Analysis of Expedited Regulatory Review Time of Marketing Authorization Applications for New Anticancer Drugs in the US and EU'. *Clinical and Translational Science*, 15(8), pp. 1959–1967. DOI: 10.1111/cts.13308.

Cutler, D., Kirson, N. and Long, G. (2020) 'Financing Drug Innovation in the US: Current Framework and Emerging Challenges'. *PharmacoEconomics*, 38(9), pp. 905–911. DOI: 10.1007/s40273-020-00926-2.

Dagenais, S. *et al.* (2022) 'Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design'. *Clinical Pharmacology and Therapeutics*, 111(1), pp. 77–89. DOI: 10.1002/cpt.2480.

Detela, G. and Lodge, A. (2019) 'EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation'. *Molecular Therapy Methods & Clinical Development*, 13, pp. 205–232. DOI: 10.1016/j.omtm.2019.01.010.

Dhiman, S.K. and Dureja, H. (2021) 'Comparative Analysis of Evolution of Regulatory Environment in USA, Europe and Japan'. *The Pharma Innovation Journal*. DOI: https://doi.org/10.22271/tpi.2021.v10.i2a.5657.

Djordjevic, D., McFadyen, A. and Anderson, J.A. (2023) 'Ethical Challenges and Opportunities in the Development and Approval of Novel Therapeutics for Rare Diseases'. *The Journal of Medicine Access*, 7, p. 27550834231177507. DOI: 10.1177/27550834231177507.

Dombeck, C. *et al.* (2022) 'Stakeholders' Views on the Most and Least Helpful Aspects of the ICH E6 GCP Guideline and Their Aspirations for the Revision of ICH E6(R2)'. *Contemporary Clinical Trials Communications*, 29, p. 100983. DOI: 10.1016/j.conctc.2022.100983.

Eichler, H. *et al.* (2019) 'Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?' *Clinical Pharmacology and Therapeutics*, 105(5), pp. 1148–1155. DOI: 10.1002/cpt.1121.

EMA. (2024a) *Advanced Therapy Classification | European Medicines Agency (EMA)*. Available at: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/advanced-therapies-marketing-authorisation/advanced-therapy-classification (Accessed: 15 August 2024).

EMA. (2024b) *From Lab to Patient - Timeline | European Medicines Agency*. Available at: https://www.ema.europa.eu/en/from-lab-to-patient-timeline (Accessed: 19 March 2024).

EMA. (2023) *Use of Real-World Evidence in Regulatory Decision Making – EMA Publishes Review of Its Studies | European Medicines Agency (EMA)*. Available at: https://www.ema.europa.eu/en/news/use-real-world-evidence-regulatory-decision-making-ema-publishes-review-its-studies (Accessed: 15 August 2024).

Epps, C. *et al.* (2022) 'Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases'. *Therapeutic Innovation & Regulatory Science*, 56(6), pp. 964–975. DOI: 10.1007/s43441-022-00409-w.

Flear, M.L. (2021) 'Expectations as Techniques of Legitimation? Imagined Futures through Global Bioethics Standards for Health Research'. *Journal of Law and the Biosciences*, 8(2), p. lsaa086. DOI: 10.1093/jlb/lsaa086.

Franco, P. *et al.* (2023) 'Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries'. *Therapeutic Innovation & Regulatory Science*, 57(3), pp. 484–514. DOI: 10.1007/s43441-022-00480-3.

Fundytus, A. *et al.* (2021) 'Access to Cancer Medicines Deemed Essential by Oncologists in 82 Countries: An International, Cross-Sectional Survey'. *The Lancet. Oncology*, 22(10), pp. 1367–1377. DOI: 10.1016/S1470-2045(21)00463-0.

Gieber, L. *et al.* (2023) 'Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond'. *Pharmaceutical Medicine*, 37(3), pp. 203–214. DOI: 10.1007/s40290-023-00473-z.

Gomes, K.L.G. *et al.* (2023) 'Post-Marketing Authorisation Safety and Efficacy Surveillance of Advanced Therapy Medicinal Products in Brazil, the European Union, the United States and Japan'. *Cytotherapy*, 25(10), pp. 1113–1123. DOI: 10.1016/j.jcyt.2023.06.005.

Gonçalves, E. (2022) 'Value-Based Pricing for Advanced Therapy Medicinal Products: Emerging Affordability Solutions'. *The European Journal of Health Economics*, 23(2), pp. 155–163. DOI: 10.1007/s10198-021-01276-2.

Gotlieb, S. (2018) 'FDA's Comprehensive Effort to Advance New Innovations: Initiatives to Modernize for Innovation'. *FDA*. Available at: https://www.fda.gov/news-events/fda-voices/fdas-comprehensive-effort-advance-new-innovations-initiatives-modernize-innovation (Accessed: 3 August 2024).

Guzman, J. *et al.* (2020) 'The WHO Global Benchmarking Tool: A Game Changer for Strengthening National Regulatory Capacity | BMJ Global Health'. *BMJ*. DOI: doi:10.1136/bmjgh-2020-003181.

Hays, D.G. and McKibben, W.B. (2021) ‘Promoting Rigorous Research: Generalizability and Qualitative Research - Hays - 2021 - Journal of Counseling & Development - Wiley Online Library’. *Journal of Counseling and Development*, 99(Advancing the Counseling Profession Through Research and Publication). DOI: https://doi.org/10.1002/jcad.12365.

Hogervorst, M.A. *et al.* (2023) ‘Perspectives on How to Build Bridges between Regulation, Health Technology Assessment and Clinical Guideline Development: A Qualitative Focus Group Study with European Experts’. *BMJ Open*, 13(8), p. e072309. DOI: 10.1136/bmjopen-2023-072309.

Hoos, A. *et al.* (2015) ‘Partnering With Patients in the Development and Lifecycle of Medicines’. *Therapeutic Innovation & Regulatory Science*, 49(6), pp. 929–939. DOI: 10.1177/2168479015580384.

Horgan, D. *et al.* (2020) ‘Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion’. *Biomedicine Hub*, 5(3), pp. 130–152. DOI: 10.1159/000511678.

Horgan, D. and Kent, A. (2017) ‘EU Health Policy, Coherence, Stakeholder Diversity and Their Impact on the EMA’. *Biomedicine Hub*, 2(Suppl 1), pp. 191–201. DOI: 10.1159/000481301.

ICH. (2024) *ICH Official Web Site : ICH*. Available at: https://www.ich.org/page/mission (Accessed: 13 May 2024).

Iglesias-Lopez, C. *et al.* (2019) ‘Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States’. *Frontiers in Pharmacology*, 10. DOI: 10.3389/fphar.2019.00921.

Jackson, H. *et al.* (2024) ‘How the Structural Determinants of Health Inequities Impact Access to Prescription Medication for Pregnant Women in Australia: A Narrative Review’. *The Lancet Regional Health – Western Pacific*, 42. DOI: 10.1016/j.lanwpc.2023.100934.

Jawahar, N. and Datchayani, B. (2018) ‘Comparison of Generic Drug Application and Their Approval Process in US, Europe and Japan’. *J. Pharm. Sci. & Res*.

Khalil, A.S., Jaenisch, R. and Mooney, D.J. (2020) ‘Engineered Tissues and Strategies to Overcome Challenges in Drug Development’. *Advanced Drug Delivery Reviews*, 158, pp. 116–139. DOI: 10.1016/j.addr.2020.09.012.

Kmetty, Z. and Stefkovics, Á. (2022) ‘Assessing the Effect of Questionnaire Design on Unit and Item-Nonresponse: Evidence from an Online Experiment’. *International Journal of Social Research Methodology*, 25(5), pp. 659–672. DOI: 10.1080/13645579.2021.1929714.

Kolochavina, M. (2021) ‘A Rapid Market Access Strategy for Orphan Medicinal Products (OMPs) with Highlights Regarding the Pricing and Reimbursement Process and Barriers to Patient Use’. In Huml, R.A. (ed.) *Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives*. Cham: Springer International Publishing, pp. 333–349. DOI: 10.1007/978-3-030-78605-2_22.

Kumari, A. *et al.* (2024) 'Quality by Design in Relation to Clinical Trials'. In Jain, N.K. and Bajwa, N. (eds.) *Introduction to Quality by Design (QbD): From Theory to Practice*. Singapore: Springer Nature, pp. 353–417. DOI: 10.1007/978-981-99-8034-5_14.

Lawlor, R. *et al.* (2021) 'Accelerating Patient Access to Oncology Medicines with Multiple Indications in Europe'. *Journal of Market Access & Health Policy*, 9(1), p. 1964791. DOI: 10.1080/20016689.2021.1964791.

Lee, M. *et al.* (2019) 'Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation'. *Clinical Pharmacology and Therapeutics*, 105(4), pp. 886–898. DOI: 10.1002/cpt.1354.

Maeda, H. *et al.* (2023) 'Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan'. *JAMA Network Open*, 6(4), p. e238875. DOI: 10.1001/jamanetworkopen.2023.8875.

Makurvet, F.D. (2021) 'Biologics vs. Small Molecules: Drug Costs and Patient Access'. *Medicine in Drug Discovery*, 9, p. 100075. DOI: 10.1016/j.medidd.2020.100075.

Mellinger, C.D. and Hanson, T.A. (2020) 'Methodological Considerations for Survey Research: Validity, Reliability, and Quantitative Analysis'. *Linguistica Antverpiensia, New Series – Themes in Translation Studies*, 19. DOI: 10.52034/lanstts.v19i0.549.

Michaeli, T., Jürges, H. and Michaeli, D.T. (2023) 'FDA Approval, Clinical Trial Evidence, Efficacy, Epidemiology, and Price for Non-Orphan and Ultra-Rare, Rare, and Common Orphan Cancer Drug Indications: Cross Sectional Analysis'. *BMJ*.

Mishra, P. *et al.* (2019) 'Descriptive Statistics and Normality Tests for Statistical Data'. *Annals of Cardiac Anaesthesia*, 22(1), p. 67. DOI: 10.4103/aca.ACA_157_18.

Mohajan, H. (2020) 'Quantitative Research: A Successful Investigation in Natural and Social Sciences'. *Journal of Economic Development, Environment and People,* 9(4), pp. 52–79.

Mooghali, M. *et al.* (2024) 'Characterization of Accelerated Approval Status, Trial Endpoints and Results, and Recommendations in Guidelines for Oncology Drug Treatments from the National Comprehensive Cancer Network: Cross Sectional Study'. *BMJ Medicine*, 3(1), p. e000802. DOI: 10.1136/bmjmed-2023-000802.

Mulberg, A.E. *et al.* (2019) 'Regulatory Strategies for Rare Diseases under Current Global Regulatory Statutes: A Discussion with Stakeholders'. *Orphanet Journal of Rare Diseases*, 14(1), p. 36. DOI: 10.1186/s13023-019-1017-5.

Neuert, C.E., Meitinger, K. and Behr, D. (2023) 'Open-Ended versus Closed Probes: Assessing Different Formats of Web Probing'. *Sociological Methods & Research*, 52(4), pp. 1981–2015. DOI: 10.1177/00491241211031271.

Niazi, S.K., Mohammed Al-Shaqha, W. and Zafar, M. (2022) 'JMAHP | Free Full-Text | Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars'. *Journal of Market Access & Health Policy (JMAHP)*. DOI: https://doi.org/10.1080/20016689.2022.2147286.

Nishioka, K. *et al.* (2022) 'Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/ Risk Assessment of a Drug in Japan'. *CLINICAL PHARMACOLOGY & THERAPEUTICS*, 111(1).

Ofori-Asenso, R., Hallgreen, C.E. and De Bruin, M.L. (2020) 'Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges'. *Frontiers in Medicine*, 7. DOI: 10.3389/fmed.2020.582634.

Olopade, C.O., Olugbile, S. and Olopade, O.I. (2012) 'Issues and Challenges for Clinical Research in International Settings'. *Principles and Practice of Clinical Research*, pp. 689–699. DOI: 10.1016/B978-0-12-382167-6.00047-3.

Omae, K. *et al.* (2022) 'US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018'. *JAMA Network Open*, 5(9), p. e2230973. DOI: 10.1001/jamanetworkopen.2022.30973.

Ozuem, W., Willis, M. and Howell, K. (2022) 'Thematic Analysis without Paradox: Sensemaking and Context'. *Qualitative Market Research: An International Journal*, 25(1), pp. 143–157. DOI: 10.1108/QMR-07-2021-0092.

Park, Y.S., Konge, L. and Artino, A.R.J. (2020) 'The Positivism Paradigm of Research'. *Academic Medicine*, 95(5), p. 690. DOI: 10.1097/ACM.0000000000003093.

Perehudoff, K. *et al.* (2021) 'Impact of the European Union on Access to Medicines in Low- and Middle-Income Countries: A Scoping Review'. *The Lancet Regional Health. Europe*, 9, p. 100219. DOI: 10.1016/j.lanepe.2021.100219.

PMDA. (2024) *Regenerative Medical Products*. *Pharmaceuticals and Medical Devices Agency*. Available at: https://www.pmda.go.jp/english/review-services/reviews/0003.html (Accessed: 15 August 2024).

Purpura, C.A. *et al.* (2022) 'The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications'. *Clinical Pharmacology and Therapeutics*, 111(1), pp. 135–144. DOI: 10.1002/cpt.2474.

RAPS. (2024) *New Report Showcases a Global Regulatory Affairs Workforce of Nearly 125,000 Professionals Across the Healthcare Products Sector*. Available at: https://www.raps.org/News-and-Articles/News-Articles/2024/4/regulatory-affairs-jobs-stats (Accessed: 3 August 2024).

Renfro, L.A. and Sargent, D.J. (2017) 'Statistical Controversies in Clinical Research: Basket Trials, Umbrella Trials, and Other Master Protocols: A Review and Examples'. *Annals of Oncology*, 28(1), pp. 34–43. DOI: 10.1093/annonc/mdw413.

Ried, L., Eckerd, S. and Kaufmann, L. (2022) 'Social Desirability Bias in PSM Surveys and Behavioral Experiments: Considerations for Design Development and Data Collection'. *Journal of Purchasing and Supply Management*, 28(1), p. 100743. DOI: 10.1016/j.pursup.2021.100743.

Rouse, R. *et al.* (2018) 'Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science'. *Therapeutic Innovation & Regulatory Science*, 52(2), pp. 244–255. DOI: 10.1177/2168479017720249.

Saesen, R. *et al.* (2020) 'Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making'. *Frontiers in Pharmacology*, 11, p. 43. DOI: 10.3389/fphar.2020.00043.

Schuster Bruce, C. *et al.* (2019) 'The Use of Validated and Nonvalidated Surrogate Endpoints in Two European Medicines Agency Expedited Approval Pathways: A Cross-Sectional Study of Products Authorised 2011–2018'. *PLoS Medicine*, 16(9), p. e1002873. DOI: 10.1371/journal.pmed.1002873.

Selker, H.P. *et al.* (2019) 'Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice'. *Clinical Pharmacology and Therapeutics*, 105(4), pp. 857–866. DOI: 10.1002/cpt.1347.

Serelli-Lee, V. *et al.* (2022) (5) 'A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies'. *Journal of Personalized Medicine*, 12(5), p. 669. DOI: 10.3390/jpm12050669.

Sertkaya, A. and Franz, C. (2022) 'DEVELOPMENT AND APPROVAL COST ANALYSIS'. In *Antimicrobial Drugs Market Returns Analysis: Final Report [Internet]*. Office of the Assistant Secretary for Planning and Evaluation (ASPE). Available at: https://www.ncbi.nlm.nih.gov/books/NBK603192/ (Accessed: 15 August 2024).

Shimura, S. (2022) *A Comparative Approach of Pharmaceutical Regulation in Europe and Japan*. University of Malta.

Shizuya, T. and Miyazaki, S. (2022) 'Comparison of New Drug Indications Approved in the United States, Europe, and Japan from 2001 to 2020'. *Biological and Pharmaceutical Bulletin*.

Siegal, Y. and Shah, S. (2019) *Pharmaceutical Market Access and Pricing Strategy*. Available at: https://www.deloitte.com/ie/en/our-thinking/insights/industry/life-sciences/pharmaceutical-pricing-market-access.html (Accessed: 15 August 2024).

Simpson, S. *et al.* (2020) 'Navigating Facilitated Regulatory Pathways during a Disease X Pandemic'. *Npj Vaccines*, 5(1), pp. 1–9. DOI: 10.1038/s41541-020-00249-5.

Skydel, J.J. *et al.* (2022) 'Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017'. *JAMA Health Forum*, 3(5), p. e221158. DOI: 10.1001/jamahealthforum.2022.1158.

Stephenson, D. *et al.* (2023) 'Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop'. *Neurotherapeutics*, 20(6), pp. 1682–1691. DOI: 10.1007/s13311-023-01440-x.

Story, D.A. and Tait, A.R. (2019) 'Survey Research'. *Anesthesiology*, 130(2), pp. 192–202. DOI: 10.1097/ALN.0000000000002436.

Subbiah, V. (2023) 'The next Generation of Evidence-Based Medicine'. *Nature Medicine*, 29(1), pp. 49–58. DOI: 10.1038/s41591-022-02160-z.

Sürücü, L. and Maslakçi, A. (2020) (3) 'VALIDITY AND RELIABILITY IN QUANTITATIVE RESEARCH'. *Business & Management Studies: An International Journal*, 8(3), pp. 2694–2726. DOI: 10.15295/bmij.v8i3.1540.

SurveyMonkey. (2024) *Margin of Error Calculator (With Formula And Examples)*. *SurveyMonkey*. Available at: https://www.surveymonkey.com/mp/margin-of-error-calculator/ (Accessed: 3 August 2024).

Teixeira, T., Kweder, S.L. and Saint-Raymond, A. (2020) 'Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?' *Clinical Pharmacology & Therapeutics*, 107(3), pp. 507–513. DOI: 10.1002/cpt.1617.

Trapani, D. *et al.* (2023) 'Impact of Prior Authorization on Patient Access to Cancer Care'. *American Society of Clinical Oncology Educational Book*, (43), p. e100036. DOI: 10.1200/EDBK_100036.

Vallano, A., Pontes, C. and Agustí, A. (2023) 'The Challenges of Access to Innovative Medicines with Limited Evidence in the European Union'. *Frontiers in Pharmacology*, 14. DOI: 10.3389/fphar.2023.1215431.

Wallstreetmojo. (2019) *Sample Size (Definition, Formula) | Calculate Sample Size*. *WallStreetMojo*. Available at: https://www.wallstreetmojo.com/sample-size-formula/ (Accessed: 6 August 2024).

Wallwey, C. and Kaifez, R.L. (2023) 'Quantitative Research Artifacts as Qualitative Data Collection Techniques in a Mixed Methods Research Study - ScienceDirect'. *Methods in Psychology*, 8. Available at: https://www.sciencedirect.com/science/article/pii/S2590260123000061 (Accessed: 12 July 2024).

Wang, S. *et al.* (2022) 'An Overview of Cancer Drugs Approved through Expedited Approval Programs and Orphan Medicine Designation Globally between 2011 and 2020'. *Drug Discovery Today*, 27(5), pp. 1236–1250. DOI: 10.1016/j.drudis.2021.12.021.

Wang, Y. (2023) 'An Insider's Perspective on FDA Approval of Aducanumab'. *Alzheimer's & Dementia (New York, N. Y.)*, 9(2), p. e12382. DOI: 10.1002/trc2.12382.

Wouters, O.J. *et al.* (2021) 'Challenges in Ensuring Global Access to COVID-19 Vaccines: Production, Affordability, Allocation, and Deployment'. *The Lancet*, 397(10278), pp. 1023–1034. DOI: 10.1016/S0140-6736(21)00306-8.

Xoxi, E. *et al.* (2022) 'A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems'. *Frontiers in Medical Technology*, 4, p. 888404. DOI: 10.3389/fmedt.2022.888404.

Zyphur, M.J. and Pierides, D.C. (2020) ‘Making Quantitative Research Work: From Positivist Dogma to Actual Social Scientific Inquiry’. *Journal of Business Ethics*, 167(1), pp. 49–62. DOI: 10.1007/s10551-019-04189-6.

Appendix – Quantitative Survey questions

The purpose of this research is to explore the alignment of International Council for Harmonisation (ICH) regions in relation to the accelerated approval of first-in-class drugs. The study aims to identify the challenges pharmaceutical organizations face in obtaining regulatory approval and propose evidence-based strategies to enhance the efficiency and effectiveness of these processes. Accelerated approval pathways are crucial for ensuring that innovative treatments reach patients with unmet medical needs promptly. This research is motivated by the increasing demand for faster access to groundbreaking therapies, especially in areas such as oncology and rare diseases, where timely approval can significantly impact patient outcomes.

Participating in this study involves completing survey that will be conducted online. Your participation is voluntary, and you have the right to withdraw at any time without consequences.

Section 1: Participant Demographics and Background

1. What is your current job title?

2. How many years of experience do you have in regulatory affairs?

• 0-3

• 3-5

• 5-10

• 10-15

• More than 15

3. Which ICH region do you primarily work in?

• EU

• US

• Japan

• Other (please specify)

4. What type of organization do you work for?

• Pharmaceutical company

• Biotech company

• Contract research organization (CRO)

• Regulatory consultancy

• Other (please specify)

Section 2: Global Regulatory Landscape

5. Which regulatory framework are you most familiar with?

• EMA (EU)

• FDA (US)

• PMDA (Japan)

• MHRA

• Other (please specify)

6. How do you rate the complexity of the regulatory requirements for first-in-class drugs in your region?

• Very simple

• Simple

• Moderate

• Complex

• Very complex

7. In your opinion, how do regulatory requirements differ across ICH regions?

8. How often do you engage with regulatory agencies during the approval process?

• Rarely

• Occasionally

• When required

• Frequently

• Very frequently

Section 3: Specific Approval Challenges

9. What are the primary challenges you face in the regulatory approval process for first-in-class drugs? (Select all that apply)

• Regulatory requirements and guidelines

• Clinical trial design and endpoints

• Data quality and integrity

• Communication with regulatory agencies

• Timelines and deadlines

• Other (please specify)

10. On a scale of 1 to 5, how significant are clinical and evidentiary hurdles in delaying the approval of innovative treatments?

1. (Not significant)

2. (Slightly significant)

3. (Moderately significant)

4. (Very significant)

5. (Extremely significant)

11. Can you describe a specific regulatory or clinical challenge you have encountered?

Section 4: Organizational Strategies

12. Which strategies does your organization use to overcome regulatory challenges? (Select all that apply)

• Early engagement with regulatory agencies

•Use of accelerated approval pathways

• Investment in advanced clinical trial designs

• Collaboration with external experts/consultants

• Implementation of robust quality management systems

• Other (please specify)

13. How effective do you find these strategies in addressing regulatory challenges?

• Very effective

• Effective

• Neutral

• Ineffective

• Very ineffective

14. Can you share an example of a successful initiative your organization has undertaken to facilitate accelerated approval?

Section 5: Recommendations and Improvements

15. What improvements would you recommend to the current regulatory approval process for first-in-class drugs in your region?

• More harmonized guidelines across ICH regions

• Increased transparency and communication from regulatory agencies

• Faster review times

• Greater flexibility in clinical trial requirements

• Enhanced collaboration between regulatory agencies and pharmaceutical companies

• Other (please specify)

16. How likely do you think these improvements would enhance the efficiency of the regulatory approval process?

• Very likely

• Likely

• Neutral

• Unlikely

• Very unlikely

17. Is there any additional feedback or suggestions you would like to provide regarding the regulatory approval process for first-in-class drugs?